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ABSTRACT
Basic scientific research over the past few decades has shown some light on the complex
pathophysiology of SCI and has enhanced our understanding of some of the important factors that
contribute to the lack of regeneration following the initial traumatic injury and secondary injury
response in the adult spinal cord. These factors include both intrinsic limitations in the
regeneration capacity of mature neurons, but also a host of environmental factors which inhibit
spontaneous attempts of axon regeneration. These environmental factors include physical
barriers to axon regeneration such as fibrous and glial scars as well as molecules which actively
inhibit regeneration. Even when these barriers are removed, axons in the central nervous system
still require the appropriate stimulatory signals in order for significant regeneration to occur.
These signals may include a substrate to provide directional guidance of the extending axon
growth cones as well as neurotrophic factors to promote axon growth and survival. Thus, to
achieve a clinically meaningful regenerative response following spinal cord injury a
combinatorial therapeutic approach is likely necessary.
This thesis investigated the use of a porous collagen scaffold with aligned pores to serve
as a substrate for axon guidance and a delivery vehicle for select therapeutic agents in both full-
and hemi- resection injury models in adult rats. In the hemi-resection injury model, the treatment
groups included: a dehydrothermally (DHT) crosslinked scaffold, a carbodiimide (EDAC)
crosslinked scaffold, and an EDAC-treated scaffold delivering either soluble Nogo receptor
(sNgR), chondroitinase ABC (ChABC), or bone marrow derived mesenchymal stem cells
(MSCs).
Improvement in hindlimb function over four weeks following injury was seen in the DHT
scaffold, EDAC scaffold + ChABC, and EDAC scaffold + MSCs groups, but not in the untreated
control group. Immunohistochemical evaluation of the tissue revealed a few regenerating axons
reaching the center of the scaffold in the DHT scaffold and EDAC scaffold + ChABC groups at 4
week post injury. Histological evaluation at 4 weeks showed the defect area of all groups to be
largely comprised of loosely organized fibrous tissue. Many macrophages were seen surrounding
the defect area of all groups; however, there were significantly more macrophages within the
defect area of the control group compared to the treatment groups.
In the full-resection injury model, at 6 weeks post injury, implanted collagen scaffolds
tended to reduce the number of cystic cavities in the defect and to better align the reparative
tissue with the long axis of the spinal cord.
These results show the potential benefit of collagen scaffolds alone or in combination
with select therapeutic agents as a means to modulate the healing response following spinal cord
injury.
Thesis Supervisor: Myron Spector
Title: Professor of Orthopedic Surgery (Biomaterials), Harvard Medical School
Senior Lecturer, Department of Mechanical Engineering, MIT
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1.1 Study Motivation
There are currently 260,000 people in the United States who have suffered a
spinal cord injury (SCI) and there are approximately 12,000 new cases every year. Motor
vehicle crashes account for the majority of new SCI cases. The most common neurologic
level of injury is tetraplegia. Only less than 1% of patients with SCI experience full
neurological recovery.'
Patients with SCI often suffer profound reduction in quality of life. In addition to
suffering paralysis and the loss of sensation below the level of injury, other basic bodily
functions are often impaired including breathing, bowel and bladder control and sexual
function. As a result, sufferers of spinal cord injuries lose a great deal of their
independence. Additional complications that often arise with SCI are orthostatic
hypotension, autonomic dysreflexia, osteoporosis, chronic pain, and pressure ulcers.2
The financial toll that SCI imposes is quite staggering. Lifetime costs that are
directly attributed to SCI vary depending on the severity of injury and are as high as $3.2
million for high tetraplegia and $1 million for paraplegia.' Even a small restoration of
function through axon regeneration or tissue preservation could lead to major
improvement in the quality of life of the patient and a significant reduction in the cost of
care.
1.2 The Nervous System
The nervous system is composed of a network of cells which are distributed
throughout the body and function to transmit information as electrochemical impulses to,
from, and within the brain. The cells of the central nervous system include neurons
(which transmit information via action potentials) and glia, which support neuronal
function. Key features of a neuron are the cell body - containing the nucleus and
numerous organelles, the axon, and the dendrites. The axon of a neuron is connected to
the cell body at a location known as the axon hillock and is the process by which
impulses are transmitted. Axons vary in length, and can be up to a meter long in the
spinal cord of adult humans. Unlike the cell body, axons do not have any structures
associated with protein synthesis or assembly. Axons have a cylindrical shape and can be
either myelinated or unmyelinated. Myelination occurs when axons become wrapped in
multiple layers of Schwann or oligodendrocyte cell membranes which provide electrical
insulation to the axons resulting in improved electrical conduction. Myelinated axons
conduct nerve impulses at a considerably faster rate than unmyelinated axons.
Dendrites are the receiving ends of neurons and interact with axon terminals from
other neurons. The site of interaction between neurons is called the synapse. The
transmission across a synapse occurs through the release of neurotransmitters by the
presynaptic neuron, followed by the diffusion of the molecules across the synaptic cleft,
and culminating with the binding of the molecules to receptors on the postsynaptic
membrane resulting in the permeability of the cell membrane to certain ions. For the
transmission of an electric impulse the change of permeability of the membrane allows
for the influx of sodium ions and the efflux of potassium ions, resulting in a localized
reversal of charge of the cell membrane causing a propagation of an action potential. In
myelinated axons, electric impulses jump from one node of Ranvier to another. The
nodes of Ranvier are the small areas of myelin discontinuity along the length of the axon.
These areas of myelin discontinuity occur between the myelin coverage of one
oligodendrocyte or Schwann cell and another.
Glia, the supporting cells of the nervous system, include astrocytes,
oligodendrocytes, Schwann cells, ependymal cells, and microglia. Astrocytes are star-
like cells and are the largest of the neuroglia. Astrocytes have numerous processes which
attach to the outer surface of capillaries and play a role in blood flow regulation. Fibrous
astrocytes are involved with the repair of damaged tissue (they produce scarring) and are
found primarily within the white matter. They also help facilitate the metabolite transfer
to neurons. Protoplasmic astrocytes are found mainly in the gray matter of the brain and
spinal cord, are very closely associated with neurons, and regulate the external chemical
environment of neurons. Oligodendrocytes function to myelinate axons and are
commonly located among strands of axons, however, they can be found in both the grey
and white matter. A single oligodendrocyte can myelinate numerous axons. Schwann
cells are the counterparts to oligodendrocytes in the peripheral nervous system and a
single Schwann cell can myelinate a short segment of a single axon. Ependymal cells
line the central canal of the spinal cord and the ventricles of the brain and are responsible
for the production of cerebrospinal fluid. Finally, microglia are of mesodermal origin
and play the role of immune cells for the central nervous system. These cells are
phagocytic and respond to tissue damage.
1.3 The Spinal Cord
The spinal cord is part of the central nervous system and functions as the integral
link between the brain and the peripheral nervous system. It is protected by the spinal
vertebrae, meninges and cerebrospinal fluid. The meninges are thin fibrous membranes
which surround the spinal cord and brain. The three meninges are: the pia mater,
arachnoid mater, and the dura mater.
The two distinct regions of the spinal cord cross-section are the grey and white
matter. The grey matter is centrally located and has a butterfly shape. It is composed
primarily of neuronal and glial cell bodies. The dorsal horn of the gray matter is where
the dorsal roots, which carry sensory information, are received. The ventral horn of the
gray matter is comprised primarily of multipolar motor neurons the axons of which form
the ventral roots. The white matter, on the other hand, is composed primarily of
descending and ascending axonal tracts. Axons with common function, origin, and
destination are found within distinct tracts. Each segment of the spine has a
corresponding pair of dorsal and ventral roots. Dorsal and ventral roots stemming from a
specific segment of the spine generally innervate areas of the body at the same level as
the particular spinal segment.
The spinal cord is highly vascularized. It receives blood supply from one anterior
and two posterior spinal arteries. These arteries run longitudinally throughout the length
of the spinal cord. Venous drainage of the cord is carried out by three anterior and three
posterior spinal veins.
1.4 Injury Response of the Spinal Cord
Injury to the spinal cord results in two distinct stages of tissue damage. The first
is direct tissue damage which results from the disruption of the tissue and causes severing
of axons, breaking of blood vessels, and cell death at the injury site. The second mode of
tissue damage, or secondary tissue damage, is tissue degeneration that continues after the
initial injury. Secondary damage occurs as a result of various events which occur in
response to the acute injury. Immediately following the initial injury, there is
hemorrhaging that takes place affecting the normal oxygen and nutrient supply to the
affected tissue. The body then responds with an inflammatory response which includes
the release of cytokines such as TNFa and IL-1 IP, the infiltration of polymorphonuclear
neutrophils, activation of resident microglia, and the infiltration of monocytes. In this
hostile environment neural cells begin to die and release excitotoxins such as glutamate
which causes further neural cell death. The release of free radicals also contributes to the
extended damage to surrounding nervous tissue. As a result of oligodendrocyte death,
spared axons in the vicinity of the injury lose their myelin sheaths. As spinal tissue is lost
and removed by phagocytes, fluid-filled cysts are formed within the lesion. Dense
fibrous and glial scar formation occurs at the injury site which impedes any attempts of
the axons to spontaneously regenerate across the defect. Reactive astrocytes, which form
the glial scar, express chondroitin sulphate proteoglycans (CSPGs), which inhibit axonal
growth. Other molecules inhibitory to axon growth are found in the degenerating
oligodendrocyte myelin including: Nogo-A, myelin associated glycoprotein (MAG), and
oligodendrocyte myelin glycoprotein (OMgp). These act through the Nogo Receptor
(NgR) which is located on growth cones of regenerating axons and leads to an abortive
regeneration response.8-10
In response to being disconnected from the cell body, the distal segments of
damaged axons undergo Wallerian degeneration, whereas the proximal segments retract a
short distance from the injury site.
1.5 Clinical Management of Spinal Cord Injury (SCI)
The emphasis of the initial treatment of SCI is on decompression of the spinal
cord through realignment of the spine, removal of debris from the injury site including
bone fragments, and stabilization of the spinal column by internal fixation.
The intravenous administration of methylprednisolone in high dosages within 8
hours of injury was reported by Bracken et al. to significantly reduce the effect of
secondary injury in a multicenter randomized clinical trial. Methylprednisolone was
reported to be of benefit only if administered within the 8 hour period following spinal
cord injury. " Despite the broad acceptance of methylprednisolone as a clinical
treatment for SCI there is still considerable controversy over the efficacy of this
treatment. 1 To date there are no clinical therapies which actively promote the
regeneration of the damaged spinal cord.
1.6 Other Pre-Clinical Studies of SCI
1.6.1 Experimental SCI Models
Various experimental injury models have been adopted for studying spinal cord
injury and regeneration.13,14 Contusion, transection and chemical injury models have
been used; each with distinct advantages and disadvantages. Complete transection and
resection (i.e. complete gap injury) offers the advantage of an unambiguous lesion in
which regenerating axons can be distinguished from spared axons. Gap injuries also
provide a space for the implantation of a tissue engineering construct such as a
biodegradable scaffold. The drawback of a complete gap injury is that it is not
representative of the most common spinal cord injury in humans, which is contusion of
the spinal cord. Also, in our experience, a major problem with a complete gap injury
model is the collapse of overlying soft tissue into the defect. The collapse of tissue
occurs because the overlying bone must be removed in order to create the gap defect.
Once the bone is removed, there is no longer a barrier between the overlying soft tissue
and the spinal cord. Our preliminary data suggest that select collagen implants do not
adequately prevent the collapse of overlying tissue into the defect.
A lateral hemi-resection injury, in which a section of spinal cord tissue is removed
on one side only, also provides a well-defined area where regenerating axons can be
distinguished from spared axons and allows for the implantation of a scaffold into the
defect area. At the same time, a hemi-resection injury maintains some integrity of the
spinal cord at the lesion site, and requires less amount of bone to be removed to access
the spinal cord, which helps prevent the collapse of the overlying soft tissue into the
defect. There are many examples of spinal cord injury studies that have used a lateral
hemi-resection injury model. 15-18
1.6.2 Experimental Treatments for SCI
Many experimental SCI treatment strategies are being investigated in animal
models and being reported in the literature. Some approaches to spinal cord regeneration
involve development and evaluation of various substrates to provide guidance and act as
a bridge for axonal growth across a defect in the spinal cord. 15,19-24 The focus of some
studies is on enhancing the regenerative capacity of neurons by delivering neurotrophic
25,26factors, either directly or by gene therapy, to the injury site. Other studies have
looked at the implantation of various cell types into the damaged spinal cord to replace
27-33lost cells and facilitate nerve repair. Various stem cell approaches have been studied,
including the implantation of neural stem and progenitor cells into spinal cord lesions.34-
36 In some studies, implanted cells are first genetically encoded to express specific
neurotrophic factors.37-
40
Bone marrow mesenchymal stem cells implanted into damaged spinal cords of
adult rats have been reported to stimulate nerve regeneration. 4 1-44 Lu et al. reported that
BDNF-expressing marrow stromal cells supported axonal regeneration in adult rats.
Furthermore, olfactory ensheathing glia have been reported to promote long distance
axonal growth when implanted into the defect of a transected rat spinal cord. 30-32 In
another study, neurotrophin-3 (NT-3) expressing olfactory ensheathing glia cells were
reported to promote spinal sparing and regeneration in adult rats. 38 While some
researchers only implant cells into the spinal cord lesion others implant them in
combination with a biomaterial scaffold. 5 ,
23
,
46
The identification of inhibitors to regeneration and the application of agents to
block or overcome these inhibitors has shown promise in improving axon regeneration
after spinal cord injury. The benefit to axon regeneration of neutralizing or blocking the
activity of Nogo, MAG, and OMpg or their signaling pathway has been largely
demonstrated over the past decade.47 50 Other inhibitory molecules present following
spinal cord injury include chondroitin sulfate proteoglycans (CSPG) which are
components of the glial scar. Enzymatic degradation of CSPG using chondroitinase ABC
has been shown to facilitate enhanced axon regeneration. s,52 In most studies the method
used to deliver agents to neutralize inhibitory molecules has been by intrathecal injection.
To our knowledge, no studies have examined delivery of antagonists to inhibitors within
a biodegradable scaffold.
Notwithstanding the encouraging results reported in the literature on axon
regeneration and functional recovery in experimental spinal cord injury models, the
effects of these treatments have been limited. It is likely that a clinically effective
treatment for spinal cord injury will require a multifaceted approach to nerve
regeneration; combining various spinal cord regeneration strategies.
1.6.3 Collagen Scaffolds for Spinal Cord Regeneration
Following injury, spinal cord axons exhibit a spontaneous regenerative response
including axon regrowth and up-regulation of regeneration related genes.5 3 55 However,
it appears that one reason for the failure of this initial regenerative response is the
absence of an aligned substrate to direct the extending axons. In vitro and in vivo studies
have shown that axons grow preferentially along aligned substrates.56,57 Collagen has
been widely investigated for use in nerve regeneration. In peripheral nerve experiments,
collagen implants have facilitated regeneration of severed axons to the level of nerve
autograph, the gold standard for peripheral nerve regeneration.s8 Spilker et. al found that
collagen tubes implanted across a gap defect in a rat spinal cord reduced the density of
collagenous scar and aligned the reparative tissue with the long axis of the spinal cord.59
Building off this prior work, this thesis will investigate the use of collagen
scaffolds alone and for the delivery of select therapeutic agents to enhance a regenerative
response in spinal cord injury using full- and hemi- resection rat spinal cord injury
models.
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2.1 Methods
2.1.1 Collagen suspension preparation
Collagen scaffolds were fabricated using type 1/111 porcine collagen (Geistlich
Biomaterials). Collagen suspensions containing 0.5%, 1%, or 2% weight/volume
collagen were prepared by mixing the collagen into a solution of hydrochloric acid and
water, at a pH of 3.0. The suspension was blended at 14,000 RPM for 3 hours, with
periodic checking and adjustment of the pH to 3.0. The suspension was then centrifuged
for 15 minutes at 1000 RPM to remove air bubbles.
2.1.2 Scaffold fabrication with longitudinal pore orientation
Longitudinal pore orientation was achieved by injecting a collagen suspension
into cylindrical channels in a polyethylene mold and freezing along a longitudinal
temperature gradient. A temperature gradient was created along the length of the channel
by inserting a copper plug into one end of the channel and placing the copper plug in
contact with the freeze dryer shelf. The temperature of the freeze dryer shelf was set at -
40'C for scaffolds with smaller pore size and -15'C for scaffolds with larger pore size.
After freezing, the collagen suspension was sublimated by applying a vacuum of 200
mTorr and raising the temperature to 00 C as described previously. 60 This removes the
ice content and produce a porous, sponge-like scaffold with oriented channels.
2.1.3 Dehydrothermal crosslinking of scaffolds
Porous collagen scaffolds with longitudinally oriented pores were fabricated as
described above then were placed in a vacuum oven for 24 hours at 105'C and 50 mTorr
to dehydrothermally crosslink the scaffolds.
2.1.4 JB-4 embedding and sectioning of scaffolds for pore analysis
Collagen scaffolds were dehydrated in 100% alcohol overnight at 4'C on a
rotator. Following dehydration, samples were equilibrated for 12 hours at 4'C in a
solution of 50% ethanol and 50% catalyzed JB-4 solution A (Cat. No. 0226A-800,
Polysciences). The scaffolds were then infiltrated in 100% catalyzed JB-4 solution A on
a rotator for 1 to 4 days at 4'C with the solution being changed every 12 to 24 hours.
Once infiltration was complete, the scaffolds appeared translucent and sank to the bottom
of container. The scaffolds were then placed in a combined solution of JB-4 solution A
and JB-4 solution B (Benzoyl Peroxide, plasticized, Cat. No. 02618-12, Polysciences)
and allowed to harden within plastic molds.
Five micron thick sections of JB-4 embedded scaffolds were made using a
microtome, placed in a water bath, set on glass slides and allowed to dry overnight at
room temperature. The sections were then stained with Aniline Blue.
2.1.5 Scaffold pore size analysis
Images of 5 [tm thick sections of JB-4 embedded scaffolds were taken using a
light microscope (Olympus, BX5 1) outfitted with a digital camera. Images of both
transverse and longitudinal sections of the scaffolds were taken using a 4X objective.
Using Adobe Photoshop, the images were de-speckled, sharpened, and made binary. The
Linear Intercept method of pore size determination was used by employing a macro in
Scion Image (Scion Corporation, www.scioncorp.com) as described previously. 6 1,62
2.2 Results
2.2.1 Effect of collagen concentration on scaffold pore size
Porous cylindrical scaffolds were fabricated using a mold that produced 25 mm
long scaffolds (Figure 2.1, top image) from collagen solutions with collagen
concentrations of 0.5%, 1%, and 2% weight/volume (w/v). A 5 mm long segment was
selected from the 25 mm long cylindrical scaffolds, at the same location in all scaffolds,
for pore analysis (Figure 2.1, bottom image).
Imaging of longitudinal plastic sections of the 5 mm long scaffolds revealed pores
that were closely aligned with the long axis of the scaffold for all three collagen
concentrations tested (Figure 2.2, center column). The pores at the bottom end of the
scaffold generally appeared to be slightly larger than those at the top end, and with
increasing collagen concentration there was a decrease in pore diameter (Figure 2.2).
Quantification of the pore diameter using
the Linear Intercept method found the
average pore diameters for the bottom and
top ends of the 0.5%, 1%, and 2%
collagen scaffolds to be: 99 [tm, 109 [tm;
108 [im, 83 [im; and 80 [tm, 73 [tm,
respectively (Figure 2.3). Two-way
ANOVA revealed a statistically
significant effect of collagen
concentration on the mean pore diameter
(p<0.001, power=0.996), but did not find
Figure 2.1 Cylindrical scaffold. Top image: the location within the scaffold to have a
Example of a freeze dried 2% collagen cylindrical
scaffold, 25 mm long. Dotted black lines indicate significant effect on pore size (p=O. 12,
the location of the bottom and top ends of the 5 power=0.33). Comparison of individual
mm segment (from each scaffold) that was
analyzed and used for in vitro and in vivo studies. groups using Fisher's PLSD showed a
Bottom image: 5 mm long segment of a 2%
collagen cylindrical scaffold after being wet in an
alcohol solution. diameter between the 0.5% and 2%
2- PPRF" ....... . .
Figure 2.2 Binary images of 5 sm thick Aniline Blue stained plastic sections of porous cylindrical
scaffolds with a freeze temperature of -40'C and collagen concentrations of 0.5%, 1 %, and 2%.
Left and right columns: cross-sections of the bottom and top ends, respectively, of the 5 mm long
scaffold. Center column: longitudinal sections from the middle of the 5 mm long scaffolds showing
longitudinally oriented pore structure. Scale bar 1mm.
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Figure 2.3 Effect of collagen concentration on scaffold pore size of 5 nun long cylindrical scaffolds
Frozen at -40'C. Mean ± SEM.
collagen groups (p<0.001), as well as between the 1% and 2% groups (p=0.002), but not
between the 0.5% and 1% groups (p=0.18).
2.2.2 Effect offreeze temperature on scaffold pore size
Qualitative comparison of the pore structure of 0.5% collagen scaffolds frozen at -
15'C and -40'C showed the pore orientation to be closely aligned with the long axis of
the cylindrical scaffolds at both freeze temperatures (Figure 2.4, center column). The
pores at the bottom and top ends of the 5 mm long scaffold appeared to be similarly sized
for both freeze temperatures tested. The pores of the scaffolds with a freeze temperature
of -15'C appeared considerably larger than those of the scaffold frozen at -40'C (Figure
2.4). Quantification of the average pore diameter of the 0.5% collagen scaffolds, using
the Linear Intercept method, showed the average pore diameters for the bottom and top
ends of the scaffolds frozen at -15'C and -40'C to be: 223 ptm, 195 [tm; and 99 tm, 109
pm, respectively (Figure 2.5). Two-way ANOVA showed a significant effect of freeze
temperature on the average pore diameter (p<0.001, power= 1), but as shown above, there
was no effect of the location along the length of the scaffold on the average pore size
(p=0.6, power=0.08).
Figure 2.4 Binary images of 5 pm thick Aniline Blue stained plastic sections of porous cylindrical
scaffolds with a collagen concentrations of 0.5% and freeze temperatures of -15'C and -40'C.
Left and right columns: cross-sections of the bottom and top ends, respectively, of the 5 mm long
scaffolds. Center column: longitudinal sections from the middle of the 5 mm long scaffolds showing
longitudinally oriented pore structure. Scale bar 1mm.
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Figure 2.5 Effect of freeze temperature on scaffold pore size of 5 mm long 0.5% collagen
cylindrical scaffolds. Mean ± SEM.
2.3 Discussion
The ablity to fabricate scaffolds with longitudinally oriented pores is important
for providing directional guidance to regenerating axons. There is both in vitro and in
vivo evidence that axons grow preferentially along aligned substrates.16,s6,57,63 Here we
have shown that we were able to fabricate porous cylindrical scaffolds with
longitudinally oriented pores by adopting the method presented by Madaghiele et al. to
64directionally freeze a collagen suspension within a mold. The scaffolds were made to
have a diameter of approximately 2.8 mm - comparable to the diameter of the rat thoracic
spinal cord. The average pore size could be controlled as a function of both collagen
concentration and freeze temperature as has been reported previously. 61,64
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3.1 Introduction
Following injury, spinal cord axons exhibit a spontaneous regenerative response
including axon regrowth and up-regulation of regeneration related genes. 5 3-5 5 However,
it appears that one reason for the failure of this initial regenerative response is the
absence of an aligned substrate to direct the extending axons. In vitro and in vivo studies
have shown that axons grow preferentially along aligned substrates. 5657 Collagen has
been widely investigated for use in nerve regeneration. In peripheral nerve experiments,
collagen implants have facilitated regeneration of severed axons to the level of nerve
autograph, the gold standard for peripheral nerve regeneration.58 Spilker et. al found that
collagen tubes implanted across a gap defect in a rat spinal cord reduced the density of
collagenous scar and aligned the reparative tissue with the long axis of the spinal cord.59
This prior work motivates the further investigation of the use of collagen scaffolds
alone and for the delivery of select therapeutic agents to enhance a regenerative response
in spinal cord injury using a full-resection rat spinal cord injury model. The choice of a
full-resection defect injury model is based on its advantage of being able to clearly
distinguish regenerated tissue from spared tissue as well as provide a well-defined space
for scaffold implantation.
This experiment also evaluated the effect of incorporation of the following agents
into the collagen scaffold: (1) the basement membrane molecule, laminin, which has been
found to enhance certain aspects of the healing response in SCI; and (2) the plasmid
encoding glial cell-line derived neurotropic factor (pGDNF) into the collagen scaffold.
GDNF is one of several potent neurotrophic factors which regulate many critical
behaviors of neurons, including neurite branching and can serve as a neuroprotective
agent.66
3.2 Experimental Groups
A 5 mm full-resection (gap) was created in the adult rat thoracic spinal cord and a
collagen scaffold was implanted into the defect alone or as a delivery vehicle for cells or
select therapeutic agents. The scaffold was implanted in combination with (a) a collagen
membrane partially wrapped around the defect acting as a tube (wrap), and (b) a collagen
membrane overlying the defect area acting as a dorsal barrier. The experimental groups
were as follows:
Six week study: (1) Control group - 5 mm full-resection spinal cord injury with
dorsal barrier only (n=7); (2) Dehydrothermally (DHT) crosslinked 2% collagen scaffold
(slurry freeze temperature -40'C), plus collagen wrap and dorsal barrier (n=8); (3) DHT
crosslinked 2% collagen scaffold (slurry freeze temperature -40'C) delivering adult
neural stem cells (NSCs), plus the collagen wrap and dorsal barrier (n=8); (4) DHT
crosslinked 2% collagen scaffold (slurry freeze temperature -40'C) delivering the gene
for glial cell line-derived neurotrophic factor (GDNF), along with the collagen wrap and
dorsal barrier (n=8).
Two week study: (1) Control: 5mm gap spinal cord injury (SCI) with dorsal
barrier only (n=6); (2) Dehydrothermally (DHT) crosslinked 1% collagen scaffold (slurry
freeze temperature -40'C), plus collagen wrap and dorsal barrier (n=6); (3)
Dehydrothermally (DHT) crosslinked 1% collagen scaffold (slurry freeze temperature -
40'C), containing laminin, along with the collagen wrap and dorsal barrier (n=6); (4)
Carbodiimide crosslinked 1% collagen scaffold (slurry freeze temperature -40'C),
containing laminin, along with collagen wrap and dorsal barrier (n=6).
3.3 Methods
3.3.1 Collagen suspension preparation
Collagen scaffolds were fabricated using type I/II porcine collagen (Geistlich
Biomaterials). Collagen suspensions containing 1% or 2% weight/volume collagen were
prepared by mixing the collagen into a solution of hydrochloric acid and water, at a pH of
3.0. The suspension was blended at 14,000 RPM for 3 hours, with periodic checking and
adjustment of the pH to 3.0. The suspension was then centrifuged for 15 minutes at 1000
RPM to remove air bubbles.
3.3.2 Scaffold fabrication with longitudinal pore orientation
Longitudinal pore orientation was achieved by injecting a collagen suspension
into cylindrical channels in a polyethylene mold and freezing along a longitudinal
temperature gradient. A temperature gradient was created along the length of the channel
by inserting a copper plug into one end of the channel and placing the copper plug in
contact with the freeze dryer shelf. The temperature of the freeze dryer shelf was set at -
40'C. After freezing, the collagen suspension was sublimated by creating a vacuum of
200 mTorr and raising the temperature to 00 C as described previously. 60 This removes
the ice content and produces a porous, sponge-like scaffold with oriented channels.
3.3.3 Dehydrothermal and carbodiimide crosslinking of scaffolds
Porous collagen scaffolds with longitudinally oriented pores were fabricated as
described above then were placed in a vacuum oven for 24 hours at 105'C and 50 mTorr
to dehydrothermally crosslink the scaffolds. In some cases the scaffolds were further
crosslinked by carbodiimide treatment. A solution of carbodiimide hydrochloride
(EDAC, Sigma Cat.# E-7750) and N-hydroxysuccinimide (NHS, Sigma Cat.# H-7377)
was prepared at a EDAC:NHS molar ratio of 5:2. Scaffolds were incubated at room
temperature for 3.5 hours in the EDAC-NHS solution then the scaffolds were rinsed
twice in sterile phosphate buffered saline (PBS) for 1 hour. The scaffolds were then
stored for short term in fresh PBS at 4'C.
3.3.4 Collagen membrane to wrap and cover defect
In the current in vivo studies, the BioGide@ (Geistlich Biomaterials, Wolhusen,
Switzerland) collagen sheet was used to partially wrap, and cover the defect. It is a
collagen type 1/111 membrane that is commercially available in the US and in many
European countries. Its primary use is in certain dental and maxillofacial procedures.
The membrane has a bilayer design which combines 2 distinct layers to form the
membrane. One is a smooth dense layer which is less permeable while the second is a
porous layer which favors tissue integration. The layers were separated using fine
forceps and the smooth layer was used to wrap and cover the defect.
3.3.5 Adult neural stem cell culture
Adult neural stem cells isolated from rat brains were obtained from the Gage
laboratory at the Salk Institute (San Diego, CA). Cells were grown on tissue culture
plates coated with both poly-L-ornithine (Sigma, Cat. # P36655) and laminin (Fisher Cat.
# 354232). Cells were grown in DMEM/F12 medium (Invitrogen, Cat. # 11320-082),
containing 1mM glutamine, 1% penicillin-streptomycin (Sigma, Cat. # P4333), 1% N2
supplement (Invitrogen, Cat. # 17502-048), and 20 ng/ml FGF-2 (added just before use,
R&D Systems Cat. # 233-FB-025-CF). The media was changed every 2 to 3 days and
the cells were passaged once they reached approximately 90% confluency.
3.3.6 Seeding of scaffolds with adult neural stem cells
Scaffolds were first pre-wet in a series of 100% reagent alcohol, sterile distilled
water, and sterile PBS. The scaffolds were placed on sterile filter paper to absorb excess
PBS. The scaffolds were then moved to an agarose coated cell culture dish and then 32[1
of a cell suspension containing 1 million adult neural stem cells was pipetted onto the
ends of the cylindrical scaffold (half on each side). Scaffolds were then allowed to sit for
15 minutes at 370 C prior to adding culture medium.
3.3.7 Incorporation of GDNF plasmid into collagen scaffolds
Two percent collagen scaffolds frozen at -40'C and DHT crosslinked were pre-
wet in sterile PBS. The GenePorter2 (Genlantis, Catalog # T202015) non-viral
transfection system was used for the delivery of the GDNF plasmid (obtained from M.C.
Bohn, Ph.D., Children's Memorial Hospital, Chicago, IL). Each 5 mm long scaffold was
incubated with the GenePorter2 based lipoplex containing 2.5[ig of GDNF DNAThis
experiment also evaluated the effect of incorporation of the following agents into the collagen
scaffold: (1) the basement membrane molecule, laminin, which has been found to enhance certain
aspects of the healing response in SCI [Tysseling-Mattiace VM, Sahni V, Niece KL, Birch D,
Czeisler C, Fehlings MG, Stupp SI, Kessler JA. Self-assembling nanofibers inhibit glial scar
formation and promote axon elongation after spinal cord injury. J Neurosci 2008;28(14):3814-
23.]; and (2) the plasmid encoding glial cell-line derived neurotropic factor (pGDNF) into the
collagen scaffold. GDNF is one of several potent neurotrophic factors which regulate many
critical behaviors of neurons, including neurite branching and can serve as a neuroprotective
agent [Bohn MC. A commentary on glial cell line-derived neurotrophic factor (GDNF). From a
glial secreted molecule to gene therapy. Biochem Pharmacol 1999;57(2):135-42.]..
3.3.8 Incorporation of laminin into collagen scaffolds
One percent collagen scaffolds were fabricated as described above. Scaffolds
were first pre-wet in a series of 100% reagent alcohol, sterile distilled water, and sterile
PBS. The scaffolds were then placed on sterile filter paper to absorb excess PBS. A 25[tl
solution of laminin (BD, Cat.# 354232) containing 50 [g of laminin was pipetted onto
the scaffold and left to incubate at room temperature in a 12-well plate overnight.
3.3.9 Surgical procedure and animal care
Adult female Lewis rats (Taconic, Germantown, NY; Charles River Laboratories,
Wilmington, MA) weighing 150-175 grams were used in this study. All animal care and
surgical procedures were performed at the Veterans Administration Medical Center
Animal Research Facility (Jamaica Plain, MA). All surgical and post-operative
procedures were approved by the VA Boston Healthcare System Institutional Animal
Care and Use Committee (IACUC).
Rats were anesthetized by an intraperitoneal injection with sodium pentobarbital
(Nembutal solution, 50 mg/m, Abbott Laboratories, North Chicago, IL) at a dosage of 45
mg/kg. The hair on the back of the anesthetized rat was shaved and the
skin was cleaned with Betadine. Surgery was performed under sterile conditions. A
continuous oxygen supply was supplied to the rat during surgery. The rat was placed on
a flat operating board in a prone position and the rat's limbs were gently constrained with
rubber bands in an extended position. A longitudinal incision, 2 inches in length, was
made through the skin above the thoracic spine. The back musculature was incised along
the midline and dissected away from the vertebral column. A dorsal laminectomy was
performed between T7 and T10 using small bone rongeurs and microscissors. The dura
was opened with a surgical blade to expose about 10 mm of spinal cord. Two spinal cord
segments (T8 and T9) were removed by performing two complete transections and
removing the intervening tissue. This resulted in a 5 mm long gap in the spinal cord.
The nearest pair of spinal roots entering the intact rostral (T7) and caudal (T 10) spinal
cord was severed. Gelfoam was temporarily placed in the gap to induce hemostasis. In
the treatment groups, cylindrical scaffolds (alone or as a delivery vehicle for therapeutic
agents or cells) were placed within the gap connecting the rostral and caudal ends of the
spinal cord and a collagen membrane was used to enclose the gap by tucking the
membrane on the sides of each spinal cord stump. Another collagen membrane was
placed extradurally over the dorsal aspect of the wound site and extended 2 mm past the
spinal cord stumps on both sides of the defect.
Following placement of the respective implants, the overlying musculature was
closed with 4-0 vicryl sutures (Johnson and Johnson, Sommerville, NJ) and the skin was
closed with wound clips.
Immediate post-operative care of the animals included placement of the rat on a
heating pad to maintain body temperature, subcutaneous injection of 1-2 ml of lactated
Ringer's solution to compensate for blood loss during surgery, subcutaneous injection of
antibiotics (cefazolin sodium 100 mg, Abbot Laboratories, North Chicago, IL), and a
continuous supply of oxygen until the animal regained consciousness 4-6 hours later.
After regaining consciousness, the rats were transferred to plastic cages with fresh wood
chip bedding and free access to food and water. An analgesic, Ketofen (dose 5 mg/kg),
was administered once a day for 4 days following surgery by subcutaneous injection.
Subcutaneous injection of lactated Ringer's solution (2 ml per day) was continued for 4
days following surgery to prevent dehydration. Administration of antibiotics (cefazolin
sodium) was continued for up to 2 weeks, to prevent bladder infection, at a dosage of 35
mg/kg twice a day. Post-operatively, animals lacked normal micturition reflex and their
bladders had to be emptied manually every 12 hours using Crede's maneuver for the
duration of the study.
3.3.10 Animal sacrifice and tissue removal at 6 weeks
At 6 weeks post-injury the rats were sacrificed by carbon dioxide inhalation.
Immediately following sacrifice, the skin covering the spinal column was incised and the
site of spinal cord injury was located. The thoracic spinal column was removed using a
scalpel and surgical scissors. The extracted spine was placed in 10% buffered formalin at
4"C for a minimum of 72 hours. The intact spinal cord, including the defect area, was
removed from the extracted vertebral column using bone ronguers and fine surgical
scissors. The defect could be located during the spinal cord extraction process due to the
absence of the dorsal aspects of the T7 through T10 vertebrae which underwent
laminectomy during the spinal surgery. The extracted spinal cord was then cut at the
center of the defect using a No.11 surgical blade creating two spinal cord segments; one
rostral to the defect-center and one caudal to the defect-center.
3.3.11 Animal sacrifice and tissue removal at 2 weeks
At 2 weeks post-surgery the rats were sacrificed by carbon dioxide inhalation.
Immediately following sacrifice, the skin covering the spinal column was incised and the
site of spinal cord injury was located. The thoracic spinal column was removed using a
scalpel and surgical scissors. The extracted spine was placed in 10% buffered formalin at
4"C for a minimum of 72 hours. The extracted spine was trimmed down using bone
ronguers and surgical scissors; however, the spinal column surrounding the defect area
was left intact and the tissue specimens were then placed in a solution of EDTA (Fisher,
Cat.# S31 1-10) for 10 to 14 days to decalcify the bone surrounding the defect. The EDTA
solution was changed every other day.
3.3.12 Histology
3.3.12.1 Plastic Embedded Specimen
In the six week study, the spinal cord segment rostral to the defect-center was
embedded in epon (plastic) using a Poly/Bed 812 Embedding Kit (Catalog No. 08792,
Polysciences, Inc., Warrington, PA). Prior to embedding the specimen was post-fixed in
1% osmium tetroxide to stain for myelin. Plastic embedded specimens were mounted
onto an ultramicrotome and 1 tm thick sections were cut to capture the cross-sectional
area of the defect-center. Plastic sections containing spinal tissue were stained with
toluidine blue, to provide better contrast for light microscopy analysis, and then mounted
on glass slides and coverslipped.
3.3.12.2 Paraffin Embedded Specimen
In the 2 week study, the entire decalcified spines were embedded in paraffin,
whereas in the 6 week study only the spinal cord segment caudal to the defect-center was
embedded in paraffin using a tissue processor (HypercenterXP, Tissue Processor,
ThermoShandon, Houston, TX). Longitudinal sections of the defect were cut at 6 [tm
with a microtome, and mounted on glass slides.
Adjacent tissue sections were stained with hematoxylin and eosin (H & E) for
general observation of cellular and extracellular matrix features and Masson's Trichrome
which was used to identify the presence of collagenous tissue within the defect.
3.3.13 Statistical analysis: Sample size determination
Eight animals were included per group to allow loss of 2 to premature death, with
6 remaining for evaluation. This death rate is based on our own prior work and that of
others. Our power calculation for sample size determination is based on the desire to
determine as significant a 30% difference in a selected outcome variable with a 15%
standard deviation, and with a=0.05 and 0=0.05.
3.4 Results
3.4.1 Gross appearance of the defect at 6 weeks
Six weeks after surgery, extraction of the rat spinal cords revealed reparative
tissue completely filling the 5 mm gap between the transected cord stumps in all of the
animals from the four experimental groups analyzed at the 6-week time point. Figure 3.1
shows the defect area of an animal in the scaffold + GDNF group, which is representative
of the gross appearance of the defect in all four groups.
3.4.2 Histology at 6 weeks
Hematoxylin and Eosin (H&E)
staining of the spinal cord tissue at the
location of the defect revealed the
presence of cystic cavities in some of the
animals in all of the groups. An example
of a cystic cavity is shown in a control
animal in Figure 3.2. Quantification of
Figure 3.1 Gross appearance of an extracted the percent of animals per group
spinal cord containing the defect area from an containing cysts in the defect area larger
animal in the scaffold + GDNF group. Black
bars indicate the boundaries of the defect. Scale is than 1 mm in diameter showed 57% of the
mm.
control group, 25% of both the scaffold
alone and scaffold + NSCs groups, and 13% of the scaffold + GDNF group contained
fluid-filled cysts within the defect (Figure 3.3). Although there was a trend for fewer
number of cysts in the groups in which a scaffold was implanted (with or without cells
and/or GDNF), Fisher's Exact Test did not show a significant difference between the
control and the scaffold + GDNF groups (p=O. 12).
The tissue filling the defect of all groups at 6 weeks was largely composed of
fibrous scar as is seen in the higher magnification images in Figure 3.2; however, the
tissue in the center of the defect in the scaffold + GDNF group was notably less dense
than in the other groups. In the scaffold alone and scaffold + NSCs groups remnants of
the implanted collagen scaffold were occasionally seen; whereas, in the scaffold + GDNF
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Scaffold + GDNP.
Figure 3.2 H&E staining at 6 weeks. Boxed areas are shown on the right at higher magnification.
Asterisk - large cyst. SC - rostral spinal cord stump. Arrows indicate the center of the defect. Scale
bar left images, 1 mm, right images, 100sm.
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Figure 3.3 Percent of animals with cysts larger than 1-mm in diameter in the defect at 6 weeks.
group a large amount of the implanted scaffold was often clearly visible. Masson's
Trichrome showed intense staining for collagen in the defects of the control, scaffold
alone, and scaffold + NSCs groups; however, the collagen staining was less intense in the
scaffold + GDNF group (Figure 3.4). The collagenous tissue was generally closely
aligned with the long axis of the spinal cord in all of the treatment groups, but not in the
control group (higher magnification images, Figure 3.4).
Cross-sections of the tissue at the defect center of two animals from each group
were stained with Osmium Tetroxide, to identify myelinated axons, and Toluidine Blue
to see general features of the tissue (Figure 3.5). No myelinated axons were seen at the
defect center in any of the stained sections, except for occasionally at the periphery,
corresponding to axons from the adjacent nerve roots (not shown).
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Figure 3.4 Masson's Trichrome staining at 6 weeks. Boxed areas are shown on right at higher
magnification. Collagen stained blue (note: collagen also staining bright red in scaffold + GDNF image
corresponding to struts of the implanted scaffold). SC - rostral spinal cord stump. Arrows in right
images indicate the direction of the long axis of the spinal cord. Scale bars left images, 1 mm, right
images, 100m.
..........
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Figure 3.5 Osmium Tetroxide & Toluidine Blue stained cross-sections of the defect center at 6 weeks.
Boxed areas are shown on right at higher magnification. W - wrap. DB - dorsal barrier. Red dotted line
indicates the interface between wrap (dorsal barrier for control) and the luminal tissue. Arrows - scaffold
struts. Asterisks - blood vessels. Scale bar left images, 500 srm, right images, 50 um.
.......... -- .
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3.4.3 Histology at 2 weeks
Four experimental groups were evaluated at 2 weeks post injury. The 4 groups
were: 1) Control - dorsal barrier only; 2) DHT crosslinked scaffold + wrap + dorsal
barrier; 3) DHT scaffold + laminin + wrap + dorsal barrier; and 4) EDAC crosslinked
scaffold + laminin + wrap + dorsal barrier. In these 4 groups, tissue sections of the spinal
cord were taken leaving the surrounding tissue (including the vertebrae) intact, allowing
for a more complete evaluation of the defect.
At 2 weeks post injury, the implanted scaffold, wrap, and dorsal barrier could
clearly be seen in the treatment groups, as could the dorsal barrier in the control group
(Figure 3.6). In the three treatment groups, the tissue in the defect area was very loosely
organized and the implanted scaffolds did not yet have a dense ingrowth of tissue. At 2
weeks, the defect area in the control group animals already contained a band of fibrous
tissue filling the gap between the cut spinal cord stumps, with a denser organization than
was seen in the treatment groups.
In all of the groups there was a narrowing of the spinal canal within the defect.
The bone on the dorsal aspect of the spinal canal was removed during surgery
(laminectomy) to be able to access the spinal cord and create the gap injury. As a result,
overlying soft tissue was able to press against, or collapse into, the defect area resulting
in a narrowed spinal canal within the defect. The narrowing of the spinal canal occurred
to a greater extent in the control and DHT scaffold alone groups (down to approximately
35% of the original diameter) compared to the DHT scaffold + laminin and EDAC
scaffold + laminin groups (down to approximately 60% of the original diameter) (Figure
3.7). One-way ANOVA showed a significant difference among the groups for the
diameter of the spinal canal in the defect (as a percentage of the original diameter)
(p=0.003, power-0.95). Comparisons of individual groups using Fisher's PLSD showed
a significant difference between the control and the DHT scaffold + laminin groups
(p=0.01), control and EDAC scaffold + laminin groups ((p=0.00 2), DHT scaffold and
DHT scaffold + laminin groups (p=0.01), and the DHT scaffold and EDAC scaffold +
laminin groups (p=0.002 ). There was no significant difference between the control and
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Figure 3.6 Masson's Trichrome staining at 2 weeks. Boxed areas are shown on right at higher
magnification. Collagen stained blue. Note: collagen also staining bright red in struts of the implanted
scaffolds as well as in the wrap and dorsal barrier. Asterisks - implanted scaffolds. W - wrap. DB -
dorsal barrier. SC - spinal cord stump. V - vertebral body. M - muscle. Scale bars left images, 1 mm,
right images, 500sm.
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Figure 3.7 Diameter of the spinal canal within the defect. Mean ± SEM.
DHT scaffold alone groups or between the DHT scaffold + laminin and the EDAC
scaffold + laminin groups.
3.4.4 Functional ability
Immediately following spinal cord injury, all animals lost bladder function. None
of the animals regained bladder function prior to sacrifice (in both the 6 week and 2 week
studies), requiring manual bladder expression throughout the duration of both studies.
All of the animals also had complete loss of hindlimb function following injury. There
was no recovery of hindlimb function in any of the animals up to the time of sacrifice.
3.5 Discussion
Fluid-filled cysts commonly form within the lesson following spinal cord injury
in rats and in humans.54,67,68 The precise reason for cyst formation is not clearly known
but is likely related to extensive tissue necrosis within and surrounding the location of
injury. Fluid-filled cysts present a physical barrier to any attempt of severed axons or
collateral branches of uninjured axons to grow past the lesion area. In the present study,
we found a reduction in the occurrence of cysts within the defect area at 6 weeks after
injury when a porous collagen scaffold was implanted alone, or as a delivery vehicle for
neural stem cells or the gene for glial derived neurotrophic factor (GDNF). Although this
effect was not statistically significant, the trend does suggest that an implanted scaffold
may play a role in minimizing cyst formation when there is significant loss of tissue,
possibly simply as an effect of filling the initial tissue void thereby allowing for a more
complete filling of adjacent necrotic areas once the debris is cleared by phagocytes. In
the current work, there was a trend for an even lower rate of cyst formation in the
scaffold + GDNF group which could possibly be a result of the neuroprotective effects of
GDNF on spared neurons adjacent to the implanted scaffold.69-72
Another major feature of the injury response following trauma to the spinal cord
is a robust infiltration of fibroblasts and the formation of fibrous scar tissue at the
location of injury. The infiltrating fibroblasts are largely of meningeal origin but may
also originate from surrounding connective tissue in the case when the dura mater is
compromised. Several studies have shown a benefit either through functional recovery or
enhanced axon regeneration when the extent of the formation of fibrous scar tissue is
reduced.75 78 Although collagen itself does not inhibit axonal growth, the presence of a
fibrous scar within the spinal cord is seen to act as a physical barrier to regenerating
axons as well as potentially act as a binding matrix for other ECM molecules which are
inhibitory.
In the current work we observed, at 6 weeks post injury, an extensive presence of
fibrous scar tissue filling the defect area of the control, scaffold alone, and scaffold +
NSCs groups, and to a lesser extent the scaffold + GDNF group. An important difference
in the quality of the fibrous tissue between the control group and all three treatment
groups was the alignment of the collagenous tissue. In the treatment groups, the scar
tissue filling the defect was closely aligned with the long axis of the spinal cord, whereas
in the control the scar tissue filling the defect did not have this alignment. This
observation is consistent with a study by Spilker et al. who found that implanted collagen
tubes in a gap injury model in rats induced a more favorable alignment of the scar tissue
compared to control.59 Producing longitudinal alignment of the reparative tissue within a
spinal cord defect is likely an important component of creating a more permissive
environment for regenerating or collateral axons to enter and pass through the defect area.
Preliminary evaluation of the cross-section of the defect center, 6 weeks after
injury, did not show the presence of myelinated axons in any of the experimental groups
in the limited number of samples analyzed. However, the absence of myelinated axons
does not preclude the possibility of unmyelinated axons within the defect. Further
evaluation of the tissue can be done to better assess the presence of any regenerating
nerve fibers.
To better evaluate how well the implanted collagen scaffolds are able to
completely fill the defect area and maintain a space that is permissive to regenerating
axons, scaffolds were again implanted into a gap defect; however, at the time of sacrifice
instead of dissecting out the spinal cord at the location of the defect, the surrounding
spinal canal was left intact and sections were made of the entire spine. This was done to
be able to better assess the continuity of the scaffold with the adjacent spinal cord stumps,
which was difficult to accurately determine when the spinal cord tissue was dissected out
of the spinal canal. Analysis of the tissue at 2 weeks post injury found the implanted
collagen scaffold and implanted collagen membranes to be clearly visible and mostly
intact with no evidence of significant degradation for both the dehydrothermally (DHT)
crosslinked only and DHT plus carbodiimide (EDAC) crosslinked scaffolds (With or
without laminin). Also, at the 2 week time point there was no dense cell infiltration into
the scaffolds or fibrous tissue yet filling the defect area. Thus, at 2 weeks following
injury, which is roughly when increased axonal sprouting occurs,53 ,, the implanted
scaffolds appear physically permissive to the ingrowth of axons. Despite this
observation, however, it was found that there was significant narrowing of the spinal
canal at the location of the defect. Because the bone on the dorsal side of the spinal canal
at the injury location was removed during surgery in order to access the cord and create
the gap injury, the overlying soft tissue was able to press or collapse onto the defect area
resulting in a narrowing of the spinal canal at the defect. In clinical situations of spinal
cord injury in humans, the immediate priority is to decompress the spinal cord and
stabilized the spine to prevent further tissue damage. Thus, a limitation of the 5 mm
complete resection injury model adopted in this study is the inability to adequately
prevent the compression of the spinal cord at the location of the defect following surgical
laminectomy.
There was no recovery of bladder or hindlimb function up to 6 weeks following
injury in any of the animals in this study. However, the extreme severity of a 5 mm
complete resection spinal cord injury model makes it very unlikely there will be
functional recovery by 6 weeks for any treatment method.
Chapter 4
Collagen Scaffolds in a Hemi-
Resection Spinal Cord Injury
Model: Functional Evaluation
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4.1 Introduction
To extend the work presented so far in this thesis investigating the use of collagen
scaffolds for spinal cord injury in a full-resection injury model, we also looked at the use
of collagen scaffolds in a lateral hemi-resection injury, in which a section of spinal cord
tissue is removed on one side only. A hemi-resection injury also provides a well-defined
area where regenerating axons can be distinguished from spared axons and, like the full-
resection model, allows for the implantation of a scaffold into the defect area. At the
same time, however, a hemi-resection injury maintains some integrity of the spinal cord
at the lesion site, and requires less amount of bone to be removed to access the spinal
cord, which helps prevent the complication of collapse of the overlying soft tissue into
the defect. A hemi-resection injury is also much less severe than a full-resection injury
and allows for the evaluation of functional improvement of the animals. Furthermore, it
is also a more clinically relevant injury model, and has been used in several other pre-
clinical spinal cord injury studies.15-18
4.2 Experimental Groups
A 3 mm hemi-resection injury was created in the adult rat thoracic spinal cord and
a collagen scaffold was implanted into the defect alone or as a delivery vehicle for cells
or select therapeutic agents. The scaffold was implanted in combination with a collagen
membrane overlying the defect area acting as a dorsal barrier. All animals were
sacrificed 4 week after injury. The experimental groups were as follows: (1) Control
group - 3 mm hemi-resection spinal cord injury (n=6); (2) Dehydrothermally (DHT)
crosslinked 2% collagen scaffold (slurry freeze temperature -15'C), plus dorsal barrier
(n=7); (3) Carbodiimide (EDAC) crosslinked 2% collagen scaffold (slurry freeze
temperature -15'C) along with dorsal barrier (n=7); (4) EDAC crosslinked 2% collagen
scaffold (slurry freeze temperature -15'C) delivering soluble Nogo receptor (NgR), plus
the dorsal barrier (n=6); (5) EDAC crosslinked 2% collagen scaffold (slurry freeze
temperature -15'C) delivering chondroitinase ABC (ChABC), plus the dorsal barrier
(n=8); (6) EDAC crosslinked 2% collagen scaffold (slurry freeze temperature -150 C)
delivering bone marrow derived mesenchymal stem cells (MSCs), plus the dorsal barrier
(n=8).
4.3 Methods
4.3.1 Collagen suspension preparation
Collagen scaffolds were fabricated using type 1/111 porcine collagen (Geistlich
Biomaterials). Collagen suspensions containing 2% weight/volume collagen were
prepared by mixing the collagen into a solution of hydrochloric acid and water, at a pH of
3.0. The suspension was blended at 14,000 RPM for 2 hours, with periodic checking and
adjustment of the pH to 3.0. The suspension was then centrifuged for 15 minutes at 2000
RPM to remove air bubbles.
4.3.2 Scaffold fabrication with longitudinal pore orientation
Longitudinal pore orientation was achieved by injecting a collagen suspension
into cylindrical channels in a polyethylene mold and freezing along a longitudinal
temperature gradient. A temperature gradient was created along the length of the channel
by inserting a copper plug into one end of the channel and placing the copper plug in
contact with the freeze dryer shelf. The temperature of the freeze dryer shelf was set at -
15'C. After freezing, the collagen suspension was sublimated by applying a vacuum of
200 mTorr and raising the temperature to OC as described previously. 60 This removes
the ice content and produces a porous, sponge-like scaffold with oriented channels.
4.3.3 Dehydrothermal and carbodiimide crosslinking of scaffolds
Porous collagen scaffolds with longitudinally oriented pores were fabricated as
described above then were placed in a vacuum oven for 24 hours at 105'C and 50 mTorr
to dehydrothermally crosslink the scaffolds. In some cases the scaffolds were further
crosslinked by carbodiimide treatment. A solution of carbodiimide hydrochloride
(EDAC, Sigma Cat.# E-7750) and N-hydroxysuccinimide (NHS, Sigma Cat.# H-7377)
was prepared at a EDAC:NHS molar ratio of 5:2. Scaffolds were incubated at room
temperature for 3.5 hours in the EDAC-NHS solution then the scaffolds were rinsed
twice in sterile phosphate buffered saline (PBS) for 1 hour. The scaffolds were then
stored for short term in fresh PBS at 4'C.
4.3.4 Collagen membrane to wrap and cover defect
In the current in vivo studies, the BioGide@ (Geistlich Biomaterials, Wolhusen,
Switzerland) collagen sheet was used to partially wrap and cover the defect. It is a
collagen type 1/111 membrane that is commercially available in the US and in many
European countries. Its primary use is in certain dental and maxillofacial procedures.
The membrane has a bilayer design which combines 2 distinct layers to form the
membrane. One is a smooth dense layer which is less permeable while the second is a
porous layer which favors tissue integration. The layers were separated using fine
forceps and the smooth layer was used to wrap and cover the defect.
4.3.5 Rat bone marrow mesenchymal stem cell harvesting and culture
Rat mesenchymal stem cells (MSCs) were harvested from the bone marrow of the
femurs and tibias of 5 to 7 week old male Lewis rats. Under sterile conditions, the tibias
and femurs were removed from the animals and the bones were thoroughly cleaned with
a knife to remove attached muscle, periosteum, cartilage and ligaments. Using a 20
gauge needle attached to a 5 ml syringe, a small hole was made at each end of the bones
and the bone marrow was flushed out with culture media, collected and filtered with a 70
[tm cell filter. The culture medium consisted of low-glucose Dulbecco's Modified Eagle
Medium (DMEM), 20% fetal bovine serum (FBS), 1% antibiotics, and 10 ng/ml of FGF-
2. The cells were centrifuged, rinsed with Phosphate Buffered Saline (PBS) and
resuspended in culture medium. Cells from one rat were plated in one 75cm2 cell culture
flask and cultured at 37"C with 5% CO 2. After 24 hours the non-adherent cells were
removed (by medium change) and the attached cells were cultured until they grew to
approximately 75% confluency. The culture medium was changed every other day.
Once confluent, the primary culture cells were washed with PBS and detached by
incubation with Trypsin and EDTA. Detached cells were counted and frozen for future
use in aliquots of 0.5 to 0.7 ml at a cell concentration of 1 million cells per ml.
4.3.6 Seeding of scaffolds with rat bone marrow mesenchymal stem cells
Scaffolds were first pre-wet in a series of 100% reagent alcohol, sterile distilled
water, and sterile PBS. The scaffolds were placed on sterile filter paper to absorb excess
PBS. The scaffolds were then submerged in a 25[1 cell suspension within a
microcentrifuge tube containing 300,000 cells. The scaffolds were then moved to an
agarose coated cell culture dish allowed to sit for 10 minutes at 37'C prior to adding
culture medium.
4.3.7 Incorporation of soluble Nogo receptor into collagen scaffolds
Pre-wet carbodiimide crosslinked scaffolds were briefly dried on filter paper,
then 25 RI of a 9.8 mg/ml solution of soluble nogo receptor (Biogen Idec) was added to
each scaffold. The scaffolds were then freeze dried, and again 25 1A of a 9.8 mg/ml
solution of soluble nogo receptor (Biogen Idec) was added to each scaffold.
4.3.8 Incorporation of chondroitinase ABC into collagen scaffolds
Pre-wet carbodiimide crosslinked scaffolds were briefly dried on filter paper,
then 25 1A of a 10 Units/ml chondroitinase ABC solution was added to each scaffold just
prior to implantation.
4.3.9 Surgical procedure and animal care
Adult female Lewis rats (Taconic, Germantown, NY; Charles River Laboratories,
Wilmington, MA) weighing 150-175 grams were used in this study. All animal care and
surgical procedures were performed at the Veterans Administration Medical Center
Animal Research Facility (Jamaica Plain, MA). All surgical and post-operative
procedures were approved by the VA Boston Healthcare System Institutional Animal
Care and Use Committee (IACUC).
Rats were anesthetized by an intraperitoneal injection with sodium pentobarbital
(Nembutal solution, 50 mg/ml, Abbott Laboratories, North Chicago, IL) at a dosage of 45
mg/kg. The hair on the back of the anesthetized rat was shaved and the
skin was cleaned with Betadine. Surgery was performed under sterile conditions. A
continuous oxygen supply was supplied to the rat during surgery. The rat was placed on
a flat operating board in a prone position and the rat's limbs were gently constrained with
rubber bands in an extended position. A longitudinal incision, 2 inches in length, was
made through the skin above the thoracic spine. The back musculature was incised along
the midline and dissected away from the vertebral column. A dorsal laminectomy was
performed between T7 and T10 using small bone rongeurs and microscissors. The dura
was opened with a surgical blade to expose about 10 mm of spinal cord and the dorsal
spinal artery was coagulated with a bipolar cautery. A small plastic template was placed
on the exposed spinal cord to outline the area for incision. A lateral hemisection of the
spinal cord was created by making two lateral cuts (3 mm apart) on the left side of the
spinal cord with an ultrafine surgical blade using the template as a guide. The template
was removed once the cuts were made and a midline incision was made between the two
lateral cuts. A 3-mm lateral gap was created by removing the tissue between the two
lateral cuts. In the treatment groups, semi-cylindrical scaffolds (alone or as a delivery
vehicle for therapeutic agents or cells) were placed within the defect and a collagen
membrane was placed extradurally over the dorsal aspect of the wound site and extended
2 mm past the spinal cord stumps on both sides of the defect to serve as a dorsal barrier.
Following placement of the respective implants, the overlying musculature was
closed with 4-0 vicryl sutures (Johnson and Johnson, Sommerville, NJ) and the skin was
closed with wound clips.
Immediate post-operative care of the animals included placement of the rat on a
heating pad to maintain body temperature, subcutaneous injection of 1-2 ml of lactated
Ringer's solution to compensate for blood loss during surgery, subcutaneous injection of
antibiotics (cefazolin sodium 100 mg, Abbot Laboratories, North Chicago, IL), and a
continuous supply of oxygen until the animal regained consciousness 4-6 hours later.
After regaining consciousness, the rats were transferred to plastic cages with fresh wood
chip bedding and free access to food and water. An analgesic, Ketofen (dose 5 mg/kg),
was administered once a day for 4 days following surgery by subcutaneous injection.
Subcutaneous injection of lactated Ringer's solution (2 ml per day) was continued for 4
days following surgery to prevent dehydration. Administration of antibiotics (cefazolin
sodium) was continued for 1 week, to prevent bladder infection, at a dosage of 35 mg/kg
twice a day. Post-operatively, animals lacked normal micturition reflex and their
bladders had to be emptied manually every 12 hours using Crede's maneuver until
bladder function was recovered.
4.3.10 Hindlimb functional evaluation
Rats were removed from their cages and videotaped walking in an open space
weekly until sacrifice. Hindlimb function was evaluated using a simplified functional
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scoring system based on a rating system reported by Vacanti et al. Scores from 0 to 5
were given with the evaluator blinded to the treatment group assignment. The scoring
system was as follows: 0 - no hindlimb movement; 1 - spastic uncontrolled movement in
hind limb; 2 - controlled movement of hindlimb without contribution to ambulation; 3 -
controlled movement of hindlimb with slight contribution to ambulation; 4 - controlled
movement of hindlimb with extensive contribution to ambulation; 5 - normal or near
normal hind limb function.
4.3.11 Statistical analysis: Sample size determination
Eight animals were included per group to allow loss of 2 to premature death, with
6 remaining for evaluation. This death rate is based on our own prior work and that of
others. Our power calculation for sample size determination is based on the desire to
determine as significant a 30% difference in a selected outcome variable with a 15%
standard deviation, and with a=0.05 and P=0.05.
4.4 Results
4.4.1 Return of Bladder Function
All of the animals lost their ability to empty their bladders immediately following
SCI. The number of animals per group that recovered bladder function is shown in
Figure 4.1. Similar numbers of animals recovered their bladder function prior to sacrifice
at 4 weeks in all of the groups, ranging from 55% to 85% of the animals in each of the
groups, and Fisher's Exact Test showed no significant difference among groups. The
time to bladder function return ranged from just a few days in some animals to up to 2
weeks in other animals (Figure 4.2). However, ANOVA showed no significant
difference among groups for the time to bladder function return (p=0.37; power=0.33).
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Figure 4.1 Percent of animals that recovered bladder function prior to sacrifice at 4 weeks.
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Figure 4.2 Time to bladder function return. Mean ± SEM.
4.4.2 Hindlimb Function
Immediately following the hemi-sectional SCI all animals lost control of both
hindlimbs. However, over time many of the animals showed improvement in their
hindlimb function. The number of animals per group showing improvement in hindlimb
function between week 1 and week 4 post SCI is shown in table 4.1. In the control
group, 3 out of 6 animals showed an improvement of one or more scores in both
hindlimbs, whereas in the DHT group 7 out of 7 animals showed improvement in both
hindlimbs. In the EDAC alone group, EDAC + NgR, EDAC + ChABC, and EDAC +
MSCs groups the numbers of animals showing improved left hindlimb function between
1 and 4 weeks post injury were 4 out of 7, 5 out of 7, 6 out of 8, and 7 out of 8
respectively. There was similar improvement in left and right hindlimb function in all
animals.
Statistical analysis using the paired Sign Test showed a significant improvement
in left and right hindlimb function from 1 week to 4 weeks following SCI in the DHT
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(p=0.02 left and right), EDAC + ChABC (p=0.04 left, p=0.02 right), and EDAC + MSCs
(p=0.02 left, p=0.04 right) groups. Statistical significant improvement was not seen in
the EDAC + NgR group (p=0.07 left, p=0.13 right) or in the control group (p=0.48 left
and right), (Table 4.1).
Table 4.1 Improvement of Hindlimb Function from Week 1 to 4
Number of Animals Improving One or More
Scores: Number Improved / Total Number in
p-values Group
Left Right
+1 +2or> +1 2or>
Group Left Right Score Score Total Score Scores Total
Control 0.48 0.48 1/6 2/6 3/6 1/6 2/6 3/6
DHT Scaffold 0.02 0.02 2/7 5/7 7/7 4/7 3/7 7/7
EDAC Scaffold 0.13 0.13 1/7 3/7 4/7 1/7 3/7 4/7
EDAC + NgR 0.07 0.13 2/7 3/7 5/7 2/7 2/7 4/7
EDAC + ChABC 0.04 0.02 2/8 4/8 6/8 3/8 4/8 7/8
EDAC + MSCs 0.02 0.04 4/8 3/8 7/8 0/8 6/8 6/8
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Figure 4.3 Change in hindlimb function score from 1 to 4 weeks after injury. Mean ± SEM.
Comparisons among groups showed a trend for greater functional improvement
over time in treatment groups compared to the control (Figure 4.3); however, Kruskal-
Wallis ANOVA revealed no statistically significant differences among groups for the
change in score from 1 to 4 weeks (p=0.66).
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There were similar average hindlimb function scores among all groups for both
left (Figure 4.4) and right (Figure 4.5) hindlimbs, and Kruskal-Wallis ANOVA revealed
no significant difference among groups for hindlimb function at 1 week following injury
(p=0.4 4 left, p=0.75 right) or at 4 weeks following injury (p=0.57 left, p=0.56 right). As
expected, there was a tendency for the right (spared side) hindlimb functional score of
each animal to be higher than the left (lesion side); however, statistical analysis using the
paired Sign Test showed no significant difference between left and right hindlimb
function for any of the groups.
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Figure 4.4 Left hindlimb function; lesion side. Mean ± SEM.
o 4
Pre-injury Week 1 Week 2 Week 3 Week 4
Figure 4.5 Right hindlimb function; spared side. Mean ± SEM.
4.5 Discussion
An important finding of the current study was the significant improvement in
hindlimb function from 1 to 4 weeks post injury in three of the treatment groups, that was
not seen in the control group. A significant difference in hindlimb function was not seen
when solely comparing the groups at a single time point but rather by using each animal
as its own control we found that there was a significant difference in the change of
hindlimb function with time. The three groups that showed statistically significant
improvement of hindlimb function from 1 to 4 weeks post injury were the DHT scaffold
only group, the EDAC + ChABC group, and the EDAC + MSCs group. Interestingly, the
EDAC crosslinked scaffold alone group did not show a statistically significant
improvement in hindlimb function, however, when used in combination with
chondroitinase ABC or to deliver mesenchymal stem cells, a functional benefit was seen.
In future work, it will be interesting to compare the functional improvement in the
treatment groups to the control over a longer time period to see if there is a continued
improvement in hindlimb function with increased time.
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Chapter 5
Collagen Scaffolds in a Hemi-
Resection Spinal Cord Injury
Model: Tissue Response
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5.1 Introduction
To complement the functional evaluation presented in Chapter 4, histological and
immunohistochemical analysis of the injured spinal cord tissue was done to begin to
understand how the implanted collagen scaffolds modulate the healing response in a
hemi-resection injury model.
5.2 Experimental Groups
A 3 mm hemi-resection was created in the adult rat thoracic spinal cord and a
collagen scaffold was implanted into the defect alone or as a delivery vehicle for cells or
select therapeutic agents. The scaffold was implanted in combination with a collagen
membrane overlying the defect area acting as a dorsal barrier. All animals were
sacrificed 4 week after injury. The experimental groups were as follows: (1) Control
group - 3 mm hemi-resection spinal cord injury (n=6); (2) Dehydrothermally (DHT)
crosslinked 2% collagen scaffold (slurry freeze temperature -15'C), plus dorsal barrier
(n=7); (3) Carbodiimide (EDAC) crosslinked 2% collagen scaffold (slurry freeze
temperature -15'C) along with dorsal barrier (n=7); (4) EDAC crosslinked 2% collagen
scaffold (slurry freeze temperature -15'C) delivering soluble Nogo receptor (NgR), plus
the dorsal barrier (n=6); (5) EDAC crosslinked 2% collagen scaffold (slurry freeze
temperature -15'C) delivering chondroitinase ABC (ChABC), plus the dorsal barrier
(n=8); (6) EDAC crosslinked 2% collagen scaffold (slurry freeze temperature -150C)
delivering bone marrow derived mesenchymal stem cells (MSCs), plus the dorsal barrier
(n=8).
5.3 Methods
5.3.1 Collagen suspension preparation
Collagen scaffolds were fabricated using type 1/111 porcine collagen (Geistlich
Biomaterials). Collagen suspensions containing 2% weight/volume collagen were
prepared by mixing the collagen into a solution of hydrochloric acid and water, at a pH of
3.0. The suspension was blended at 14,000 RPM for 2 hours, with periodic checking and
adjustment of the pH to 3.0. The suspension was then centrifuged for 15 minutes at 2000
RPM to remove air bubbles.
5.3.2 Scaffold fabrication with longitudinal pore orientation
Longitudinal pore orientation was achieved by injecting a collagen suspension
into cylindrical channels in a polyethylene mold and freezing along a longitudinal
temperature gradient. A temperature gradient was created along the length of the channel
by inserting a copper plug into one end of the channel and placing the copper plug in
contact with the freeze dryer shelf. The temperature of the freeze dryer shelf was set at -
15'C. After freezing, the collagen suspension was sublimated by creating a vacuum of
200 mTorr and raising the temperature to OC as described previously. 60 This removes
the ice content and produces a porous, sponge-like scaffold with oriented channels.
5.3.3 Dehydrothermal and carbodiimide crosslinking of scaffolds
Porous collagen scaffolds with longitudinally oriented pores were fabricated as
described above then were placed in a vacuum oven for 24 hours at 105'C and 50 mTorr
to dehydrothermally crosslink the scaffolds. In some cases the scaffolds were further
crosslinked by carbodiimide treatment. A solution of carbodiimide hydrochloride
(EDAC, Sigma Cat.# E-7750) and N-hydroxysuccinimide (NHS, Sigma Cat.# H-7377)
was prepared at a EDAC:NHS molar ratio of 5:2. Scaffolds were incubated at room
temperature for 3.5 hours in the EDAC-NHS solution then the scaffolds were rinsed
twice in sterile phosphate buffered saline (PBS) for 1 hour. The scaffolds were then
stored for short term in fresh PBS at 4'C.
5.3.4 Collagen membrane to wrap and cover defect
In the current in vivo studies, the BioGide@ (Geistlich Biomaterials, Wolhusen,
Switzerland) collagen sheet was used to partially wrap and cover the defect. It is a
collagen type 1/111 membrane that is commercially available in the US and in many
European countries. Its primary use is in certain dental and maxillofacial procedures.
The membrane has a bilayer design which combines 2 distinct layers to form the
membrane. One is a smooth dense layer which is less permeable while the second is a
porous layer which favors tissue integration. The layers were separated using fine
forceps and the smooth layer was used to wrap and cover the defect.
5.3.5 Rat bone marrow mesenchymal stem cell harvesting and culture
Rat mesenchymal stem cells (MSCs) were harvested from the bone marrow of the
femurs and tibias of 5 to 7 week old male Lewis rats. Under sterile conditions, the tibias
and femurs were removed from the animals and the bones were thoroughly cleaned with
a knife to remove attached muscle, periosteum, cartilage and ligaments. Using a 20
gauge needle attached to a 5 ml syringe, a small hole was made at each end of the bones
and the bone marrow was flushed out with culture media, collected and filtered with a 70
tm cell filter. The culture medium consisted of low-glucose Dulbecco's Modified Eagle
Medium (DMEM), 20% fetal bovine serum (FBS), 1% antibiotics, and 10 ng/ml of FGF-
2. The cells were centrifuged, rinsed with Phosphate Buffered Saline (PBS) and
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resuspended in culture medium. Cells from one rat were plated in one 75cm cell culture
flask and cultured at 37"C with 5% CO 2. After 24 hours the non-adherent cells were
removed (by medium change) and the attached cells were cultured until they grew to
approximately 75% confluency. The culture medium was changed every other day.
Once confluent, the primary culture cells were washed with PBS and detached by
incubation with Trypsin and EDTA. Detached cells were counted and frozen for future
use in aliquots of 0.5 to 0.7 ml at a cell concentration of 1 million cells per ml.
5.3.6 Seeding of scaffolds with rat bone marrow mesenchymal stem cells
Scaffolds were first pre-wet in a series of 100% reagent alcohol, sterile distilled
water, and sterile PBS. The scaffolds were placed on sterile filter paper to absorb excess
PBS. The scaffolds were then submerged in a 25 1 cell suspension within a
microcentrifuge tube containing 300,000 cells. The scaffolds were then moved to an
agarose coated cell culture dish and allowed to sit for 10 minutes at 37'C prior to adding
culture medium.
5.3.7 Incorporation of soluble Nogo receptor into collagen scaffolds
Pre-wet carbodiimide crosslinked scaffolds were briefly dried on filter paper,
then 25 [d of a 9.8 mg/ml solution of soluble Nogo receptor (Biogen Idec) was added to
each scaffold. The scaffolds were then freeze dried, and again 25 [1 of a 9.8 mg/ml
solution of soluble Nogo receptor (Biogen Idec) was added to each scaffold.
5.3.8 Incorporation of chondroitinase ABC into collagen scaffolds
Pre-wet carbodiimide crosslinked scaffolds were briefly dried on filter paper,
then 25 p1 of a 10 Units/ml chondroitinase ABC solution was added to each scaffold just
prior to implantation.
5.3.9 Surgical procedure and animal care
Adult female Lewis rats (Taconic, Germantown, NY; Charles River Laboratories,
Wilmington, MA) weighing 150-175 grams were used in this study. All animal care and
surgical procedures were performed at the Veterans Administration Medical Center
Animal Research Facility (Jamaica Plain, MA). All surgical and post-operative
procedures were approved by the VA Boston Healthcare System Institutional Animal
Care and Use Committee (IACUC).
Rats were anesthetized by an intraperitoneal injection with sodium pentobarbital
(Nembutal solution, 50 mg/ml, Abbott Laboratories, North Chicago, IL) at a dosage of 45
mg/kg. The hair on the back of the anesthetized rat was shaved and the
skin was cleaned with Betadine. Surgery was performed under sterile conditions. A
continuous oxygen supply was supplied to the rat during surgery. The rat was placed on
a flat operating board in a prone position and the rat's limbs were gently constrained with
rubber bands in an extended position. A longitudinal incision, 2 inches in length, was
made through the skin above the thoracic spine. The back musculature was incised along
the midline and dissected away from the vertebral column. A dorsal laminectomy was
performed between T7 and T10 using small bone rongeurs and microscissors. The dura
was opened with a surgical blade to expose about 10 mm of spinal cord and the dorsal
spinal artery was coagulated with a bipolar cautery. A small plastic template was placed
on the exposed spinal cord to outline the area for incision. A lateral hemisection of the
spinal cord was created by making two lateral cuts (3 mm apart) on the left side of the
spinal cord with an ultrafine surgical blade using the template as a guide. The template
was removed once the cuts were made and a midline incision was made between the two
lateral cuts. A 3 mm lateral gap was created by removing the tissue between the two
lateral cuts. In the treatment groups, semi-cylindrical scaffolds (alone or as a delivery
vehicle for therapeutic agents or cells) were placed within the defect and a collagen
membrane was placed extradurally over the dorsal aspect of the wound site and extended
2 mm past the spinal cord stumps on both sides of the defect to act as a dorsal barrier.
Following placement of the respective implants, the overlying musculature was
closed with 4-0 vicryl sutures (Johnson and Johnson, Sommerville, NJ) and the skin was
closed with wound clips.
Immediate post-operative care of the animals included placement of the rat on a
heating pad to maintain body temperature, subcutaneous injection of 1-2 ml of lactated
Ringer's solution to compensate for blood loss during surgery, subcutaneous injection of
antibiotics (cefazolin sodium 100 mg, Abbot Laboratories, North Chicago, IL), and a
continuous supply of oxygen until the animal regained consciousness 4-6 hours later.
After regaining consciousness, the rats were transferred to plastic cages with fresh wood
chip bedding and free access to food and water. An analgesic, Ketofen (dose 5 mg/kg),
was administered once a day for 4 days following surgery by subcutaneous injection.
Subcutaneous injection of lactated Ringer's solution (2 ml per day) was continued for 4
days following surgery to prevent dehydration. Administration of antibiotics (cefazolin
sodium) was continued for 1 week, to prevent bladder infection, at a dosage of 35 mg/kg
twice a day. Post-operatively, animals lacked normal micturition reflex and their
bladders had to be emptied manually every 12 hours using Crede's maneuver until
bladder function was recovered.
5.3.10 Transcardial perfusion and tissue removal at 4 weeks
At 4 weeks post-injury the rats were given a dose of 150 mg/kg of sodium
pentobarbital administered intraperitoneally and secured to a surgical board. A
thoracotomy was performed to expose the heart, after which a needle attached to a
peristaltic pump was inserted into the left ventricle. Heparinized saline was circulated
through the animal, followed by 4% paraformaldehyde. Following transcardial
perfusion, the thoracic spinal column was removed using a scalpel and surgical scissors.
The extracted spine was placed in 4% paraformaldehyde at 4"C for a minimum of 72
hours. The extracted spine was trimmed down using bone ronguers and surgical scissors;
however, the spinal column surrounding the defect area was left intact and the tissue
specimens were then placed in a solution of EDTA (Fisher, Cat.# S311-10) for 10 to 14 days
to decalcify the bone surrounding the defect. The EDTA solution was changed every other day.
5.3.11 Histology
The entire decalcified spines were embedded in paraffin using a tissue processor
(HypercenterXP, Tissue Processor, ThermoShandon, Houston, TX). Serial longitudinal
sections of the defect were cut at 6 tm with a microtome, and mounted on glass slides.
Adjacent tissue sections were stained with hematoxylin and eosin (H&E) for
general observation of cellular and extracellular matrix features and Masson's Trichrome
which was used to identify the presence of collagenous tissue within the defect.
5.3.12 Immunohistochemistry
The following antibodies were used in the immunohistochemical staining of
paraffin embedded tissue sections containing the defect area: Anti- a-smooth muscle
actin (Sigma, Cat.# A2547), anti-CD68 (AbD Serotec, Cat. # MCA341R), anti-GAP-43
(from the Benowitz lab), anti-GFAP (Dako, Cat.# Z0334), anti-neurofilament (Abcam,
Cat.# ab24570), and anti-Von Willebrand Factor (Dako, Cat.# A0082).
5.3.13 Statistical analysis: Sample size determination
Eight animals were included per group to allow loss of 2 to premature death, with
6 remaining for evaluation. This death rate is based on our own prior work and that of
others. Our power calculation for sample size determination is based on the desire to
determine as significant a 30% difference in a selected outcome variable with a 15%
standard deviation, and with a=0.05 and P=0.05.
5.4 Results
5.4.1 Axon regeneration
Identification of axons in and around the lesion site was done by staining for
neurofilament at 30 days post injury (Figure 5.1). A band of spared tissue on the
contralateral side of the defect was visible in all of the groups whereas a few regenerating
axons could be seen bordering the rostral and caudal ends of the defect. To help identify
axons in the process of regeneration, immunostaining was done against GAP-43 (Figure
5.2). GAP-43 positive axons were seen entering the periphery of the scaffolds in the
DHT, EDAC+ChABC, and EDAC+MSCs groups, and to a lesser extent the EDAC
Figure 5.1 Neurofilament staining. Positive stain red. d - defect. Scale bar Imm.
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Figure 5.2 GAP-43 staining (red). Representative images of the middle and the boundaries (rostral and
caudal ends) of the defect area. Scale bar 100sm.
scaffold and EDAC+NgR groups. In some cases, GAP-43 positive axons were seen
reaching the center of the scaffold in the DHT and EDAC+ChABC groups. Some GAP-
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43 positive axons were seen boarding the defect of the control group with few axons
entering the defect area (Figure 5.2).
5.4.2 Angiogenesis
Staining for Von Willebrand Factor (vWF) revealed new blood vessel formation
in the defects of all groups at 30 days after injury (Figure 5.3). The implanted scaffolds
were permissive to the ingrowth of vasculature; however, the control group had
considerably more blood vessels and vWF positive cells in the defect (Figure 5.4). The
number of blood vessels in the treatment groups was similar to the quantity seen in
normal spinal cord tissue. One-way ANOVA analysis showed a significant difference
among groups for the number of blood vessels and vWF positive cells within the defect
(p=0.00 3 , power=0.95). Analysis between individual groups using Fisher's PLSD
revealed significantly more blood vessels in the defect of the control group compared to
all of the treatment groups, but showed no significant differences among the treatment
groups.
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Figure 5.4 Number of formed blood vessels and individual vWF positive cells in the defect. Mean
SEM.
5.4.3 Inflammatory response
Staining for CD68, a marker for macrophages, revealed extensive presence of
macrophages within the defect in the control group and immediately surrounding the
defect of all groups (Figure 5.5). Considerable numbers of CD68 positive cells were also
seen within the undamaged cord up to several millimeters away from the defect in both
the rostral and caudal directions of all groups. Areas of necrotic debris had an especially
high number of macrophages present. Quantification of the number of CD68 positive
cells was done at the center of the defect (corresponding to the center of the scaffold for
the treatment groups) shown in Figure 5.6. Many more macrophages were found in the
defect center of the control group than any of the other groups (Figure 5.7), and one-way
ANOVA showed this difference to be statistically significant (p<0.001, power= 1).
Comparison between individual groups using Fisher's PLSD revealed a significant
difference between the control group and each of the treatment groups (p<0.0001). There
was also a significant difference between the EDAC and EDAC+NgR groups (p=0.01) as
......................... - :r.::::::. A - ,
well as between the EDAC+NgR and EDAC+MSCs groups (p=0.03). The difference
between the DHT scaffold and EDAC scaffold alone groups was not significant (p=O. 19)
nor was the difference between the EDAC and EDAC+ChABC groups (p=0.07).
Figure 5.5 CD68 staining. Positive stain red. d - defect. Scale bar 1mm.
92
r
 
T
-t 
A 
, 
I
&
 
*
 
&
y 
%
-ci
4 
t
a(
4K
I
54
so
o
A
x 
e
u
. 
u
tYI 
o
800
700
600 -
500 -
400 -
U 300 -
200 -
100 -
0-
DHT
caffol
EDAC EDAC+ EDAC+ EDAC+
d Scaffold NgR ChABC MSCs
Figure 5.7 Number of CD68 positive cells in the defect. Mean ± SEM.
5.4.4. Fibrous tissue
The tissue filling the defects of all groups at 30 days post injury contained a large
amount of collagen as was seen by staining with Masson's Trichrome (Figure 5.8).
Closer examination of the tissue in the defect showed a loose organization of fibrous
tissue in all of the groups (Figure 5.9) with many fibroblast-like cells within the tissue. In
the treatment groups, remnants of the implanted scaffolds were often present.
I1
Control
Lesion S
Figure 5.8 Masson's Trichrome staining. Collagen stained blue/green. Scale bar 1 mm.
............ ........
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Figure 5.9 Masson's Trichrome staining at the defect center. Collagen stained blue/green. Scale bar
100pm.
5.4.5 Astrocyte response
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Figure 5.10 GFAP staining. Positive stain red.
Defect area outlined by black line. Scale bar 1mm.
The astrocyte response to injury
was assessed by GFAP staining at 30 days
following injury. There were few to no
GFAP positive astrocytes seen within the
defect areas of any group (Figure 5.10).
Astrocytes were seen immediately
bordering the lesion, and the intensity of
the GFAP staining diminished gradually at
a distance from the injury site.
5.4.6 a-smooth muscle actin
A few tissue sections from the
control and EDAC scaffold groups were
stained for a-smooth muscle actin (a-
SMA) to identify cells within and around
the defect expressing the myofibroblast
phenotype. Although many of the cells in
the defect appeared to be fibroblasts, there
were no fibroblast-like cells which stained
positively for a-SMA within the tissue
sections stained at 30 days post injury.
The only cells that were seen to stain
positive for a-SMA in and around the
defect were smooth muscle cells lining the
blood vessels (Figure 5.11). An
interesting but unexplained finding was the
positive a-SMA staining of cells with
motor neuron morphology in the grey
mater a few millimeters away from the
.............
defect (not shown). Positive a-SMA staining was not seen in motor neurons found in
sections of uninjured rat spinal cord.
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Axons in the adult CNS have, at least to some degree, the ability to initiate a
regenerative response following injury.5''" An important factor determining the degree
to which a regenerative response occurs is the permissiveness of the environment into
which growing axons enter. It is interesting to note that more primitive vertebrates such
as newts and salamanders have the ability spontaneously regenerate their spinal cords
following injury. Work by Zukor et al. has shown that the newt's ability to regenerate its
spinal cord is likely related to a more permissive environment for regeneration following
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injury compared to that seen in mammals.8 Notably, there is a lack of dense scar
formation following injury but instead meningeal and endothelial cells synthesize a loose
ECM with minimal chondroitin sulfate proteoglycan (CSPG) expression and a subdued
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astrocyte response to injury. In fact, the meninges appear to regenerate ahead of re-
growing axons, with the regenerating axons being guided by the regenerating meninges.
In embryonic mammals, spinal cord regeneration also occurs spontaneously, and a
key feature of the injury response is the lack of formation of a dense fibroblastic or glial
scar,83 but likely equally important is the presence of axon guidance cues, in the form of
both soluble and insoluble proteins, which play a vital role in directing neurite outgrowth
during development.10 A key role of the implanted scaffolds in the present work was to
provide directional guidance to re-growing nerve fibers.
We also evaluated various features of the injury response within the defect at 4
weeks including blood vessel formation, macrophage response, fibrous scar formation,
and the astrocyte response.
Blood vessel formation is an integral part of the body's healing response and an
important factor to consider when employing tissue engineering strategies for tissue
regeneration. In all of the treatment groups in this study, the implanted collagen scaffolds
were found to be permissive to the ingrowth of vasculature. Interestingly, the degree of
blood vessel formation was greater in the defect of the control than in any of the
treatment groups or that of the uninjured spinal cord. This could be due, in part, to the
higher density of macrophages in the defect of the control which may result in increased
expression of neoangiogenic factors.
Macrophages play a complex role in the healing response of the injured spinal
cord. They are key players in the clearing of necrotic debris at the site of injury and also
as part of the Wallerian degeneration that occurs in the distal ends of severed axons."
Furthermore, they have been implicated in both tissue destructive (primarily through the
release of inflammatory cytokines and reactive oxygen and nitrogen intermediates) and
tissue regenerative/protective (by the release of growth promoting and neuroprotective
factors) processes following spinal cord injury.68,79,85,86 A striking demonstration of the
seemingly dual role of macrophages following spinal cord injury is a study by Kostyk et
al. that showed a paradoxical association between a marked increase in axon regeneration
and an impaired functional recovery in MRL/MpJ mice, which have been shown to have
scarless regeneration of ear puncture injury and a substantially reduced macrophage
response following spinal cord injury.87 Interestingly, in the newt, axon regeneration
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occurs in the presence of a significant inflammatory response which includes macrophage
and lymphocyte infiltration, however this response does not seem to be detrimental to
82axonal growth. Still others have shown the benefits of macrophage activation on axon
regeneration in the mouse optic nerve,88 and rat spinal cord.89 The dichotomy between
the protective and destructive effects of the macrophage response is likely the result of
distinctive macrophage phenotypes resulting in dramatically different behavior. 89
In the present study, at 4 weeks we found a robust macrophage response in the
tissue immediately surrounding the defect area as well as in the white matter tracts distant
from the lesion site in all of the experimental groups. However, only a few macrophages
were seen in the scaffolds of the treatment groups, whereas in the control group there
were a large number of macrophages filling the defect area. This suggests the continued
presence of necrotic debris in the defect of the control group, to which macrophages are
responding, and the absence of substantial stimulation of macrophages to migrate into the
scaffold, at 4 week post injury. Interestingly, the addition of the soluble Nogo receptor to
the EDAC-treated scaffold resulted in a significant increase in the number of
macrophages within the scaffold at 4 weeks, suggesting an inflammatory response to the
presence of the Nogo receptor.
Similar to the macrophages, astrocytes have been shown to have both beneficial
and detrimental effects on the healing response in the injured spinal cord.90 In the acute
stage of injury astrocytes are activated, become hypertrophied, proliferate, and migrate to
the site of injury. This response serves to isolate and contain the injury site in an attempt
to prevent further damage to the surrounding tissue. 91,92 Astrocytes also respond to injury
by synthesizing a scar tissue that is rich in chondroitin sulfate proteoglycans (CSPGs)
which are inhibitory to axonal growth.93 94 Thus, at early time points following injury
astrocytes appear to have a protective effect, however, this benefit comes at the expense
of impaired axon regeneration once a glial scar has been formed.
In our present work, we observed a modest increase in the number of astrocytes
present at the boundary of the defect area in all groups, with only a few entering into the
implanted scaffolds. This seems to suggest the ability of the astrocytes to enter the
scaffolds but an absence of signaling to stimulate any considerable astrocyte migration
within the scaffolds at 4 weeks.
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Similar to the results of the full-resection injury model presented in Chapter 3, the
defect area of all groups in the hemi-resection injury model was comprised largely of
collagenous tissue. A key difference however in the quality of the collagenous tissue was
that in the hemi-resection defect the tissue was considerably more loosely organized at
the 4 week time point, resulting in a more favorable environment for regenerating axons.
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Chapter 6
Conclusions
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6.1 Contributions of this Thesis
This thesis has contributed to our understanding of:
(a) The utility of 2 animal models for the investigation of the contribution of select
therapeutic approaches for the treatment of SCI and for the study of mechanisms
underlying the outcomes of the various therapeutic approaches;
(b) The various roles that collagen biomaterials could serve in the treatment of SCI,
such as:
e a dorsal barrier to impede the musculature and connective tissue from
collapsing into SCI defects
e a wrap to facilitate the regeneration of the dura
e a scaffold to reduce the formation of cysts and to facilitate axonal regrowth
through the defect
* a delivery vehicle for exogenous cells and regulators molecules
(c) The effects of select therapeutic molecules (GDNF plasmid, sNgR and
chondroitinase ABC) and cells (MSCs and NSCs) on the healing of certain types of
SCI defects.
This thesis also demonstrated that in a full gap spinal cord injury the presence of a
crosslinked scaffold within the defect had a significant effect on reducing the degree of
spinal canal narrowing when compared to a defect treated with a dorsal barrier alone.
Maintaining the diameter of the spinal canal is important in preventing possible
obstruction to the regenerating spinal cord. Furthermore, the reparative tissue in the full
gap defect at 6 weeks was more aligned with the long axis of the spinal cord in animals
implanted with collagen scaffolds (with longitudinally oriented pores), compared to the
controls. The finding is important in light of the fact that axons grow preferentially along
aligned substrates.
In a hemi-resection model this thesis demonstrated that a collagen scaffold alone
improved the recovery of function from 1 to 4 weeks post-SCI compared to the untreated
control. This thesis also showed that a collagen scaffold implanted into a hemi-resection
injury was able to modulate the healing response by:
- Enabling some regenerating axons to enter and reach the center of the scaffold.
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- Providing an environment that is permissive to the ingrowth of vasculature similar
to the degree seen in normal spinal cord tissue.
- Reducing the number of macrophages in the defect center compared to the
control, showing that the scaffold can affect the macrophage response which is a
critical component of the spinal cord's response to injury.
- Allowing for a more loose organization of the fibrous tissue in the defect (at 4
weeks post injury).
- Not stimulating an increased astrocyte response compared to the control, and
providing a matrix into which astrocytes could potentially migrate into.
6.2 Conclusions
This thesis showed the potential for collagen scaffolds alone and for the delivery
of select therapeutic agents to modulate the healing and enhance the regenerative
response in spinal cord injury using full- and hemi- resection rat models. SCI research to
date suggests that a combined approach is likely needed to create an environment which
is conducive to significant axon regeneration by: 1) providing a substrate to guide the
regenerating axons, 2) neutralizing or removing inhibitory molecules, and 3) providing a
source of a neurotrophic and other factors to stimulate axon growth. For this reason, a
tissue engineering approach, combining the use of a biomaterial scaffold along with cells
and regulators has much promise for providing a treatment for SCI.
6.3 Limitations
As with any animal study there are limitations with respect to the degree to which
the injury in the animal models the human condition. An important limitation of using a
pre-formed scaffold as an implant for spinal cord injury is the necessity to have a well-
defined space into which the scaffold can be implanted without disrupting viable spinal
cord tissue. Thus, a major aspect of bringing a biomaterial approach for treating SCI
closer to clinical application is the development of methods to precisely and safely place
the biomaterial at the desired location within the lesion.
108
6.4 Recommendations for Future Work
In an attempt to further understand the role of collagen implants in modulating the
healing response in SCI the following are potentially valuable areas for future work:
" Assess longer survival times for animals with hemi-resection defects treated with
a DHT crosslinked scaffold, which showed beneficial effects at 4 weeks on both
hindlimb functional recovery and axon regeneration into the scaffold. Evaluating
longer survival times would provide useful information on the longer term
benefits of the treatment.
" Characterize the release kinetics of the therapeutic molecules delivered by the
scaffold and develop better controlled release methods.
" Investigate the particular phenotypes of specific cell types which respond to SCI.
For example, getting a better understanding of the phenotype of the macrophages
found in the defect area would give better insight into how the implanted scaffold
affects the pro-inflammatory versus the pro-regenerative phenotypes of
macrophages.
" Anterograde and retrograde axon tracing would allow for the identification of the
specific axon types (i.e. motor, sensory) that respond to the implanted scaffolds.
" Tracking the fate of implanted cells, such as their survival, location, and
differentiation would greatly contribute to the understanding of what roles the
cells are playing in the healing process.
" Finally, a closer evaluation of the effects of scaffold characteristics such as pore
size, degradation rate, and stiffness on the injury response is likely very important
in optimizing the regenerative potential of collagen implants.
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Preparation of 0.5% w/v collagen slurry starting from Biogide@ powder
(porcine type II collagen)
Note: The collagen should be "dissolved" in acid solution, usually at pH=3. However, if
we prepare a solution pH=3 (ex. 0.5 ml 0.1 M HCl solution + 49.5 ml distilled water) the
pH of the solution may increase up to 6-7 after adding the collagen type I/II powder. So
more acid solution needs to be added to dissolve the collagen (at pH 6-7, the collagen
powder forms big clusters).
Slurry 0.5% w/v collagen (200 ml total):
1) Add 2 ml 0.1 M HCl (0.1 M HCl --> 100pl of 6 M HCL into 5.9 ml of distilled water)
to 196 ml of distilled water.
2) Add 1 -g of collagen powder to the above solution and stir in 200 ml beaker with
magnetic stir bar. Monitor pH while stirring.
3) Add another 2 ml of 0.1 M HCl solution gradually to maintain pH of 3.
4) Blend slurry for 90 minutes at 14000 rpm. Refrigerate the system during the blending
with an ice bath.
5) Adjust the pH to 3 by adding drops of 6 M HCl.
6) Blend again for 90 minutes at 14000 rpm.
c) Centrifuge at 1000 rpm for 15 min to degas. Store the slurry at 4'C.
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Preparation of 1% w/v collagen slurry starting from Biogide@ powder
(porcine type I/III collagen)
Note: The collagen should be "dissolved" in acid solution, usually at pH=3. However, if
we prepare a solution pH=3 (ex. 0.5 ml 0.1 M HCl solution + 49.5 ml distilled water) the
pH of the solution may increase up to 6-7 after adding the collagen type 1/II powder. So
more acid solution needs to be added to dissolve the collagen (at pH 6-7, the collagen
powder forms big clusters).
Slurry 1% w/v collagen (200 ml total):
1) Add 2 ml 0.1 M HCl (0.1 M HCl --> 100pl of 6 M HCL into 5.9 ml of distilled water)
to 194 ml of distilled water.
2) Add 2-g of collagen powder to the above solution and stir in 200 ml beaker with
magnetic stir bar. Monitor pH while stirring.
3) Add 4 ml of 0.1 M HCl solution gradually to maintain pH of 3.
4) Blend slurry for 90 minutes at 14000 rpm. Refrigerate the system during the blending
with an ice bath.
5) Adjust the pH to 3 by adding drops of 6 M HCl.
6) Blend again for 90 minutes at 14000 rpm.
7) Centrifuge at 1000 rpm for 15 min to degas. Store the slurry at 4'C.
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Preparation of 2% w/v collagen slurry starting from Biogide@ powder
(porcine type I/II collagen)
Note: The collagen should be "dissolved" in acid solution, usually at pH=3. However, if
we prepare a solution pH=3 (ex. 0.5 ml 0.1 M HC1 solution + 49.5 ml distilled water) the
pH of the solution may increase up to 6-7 after adding the collagen type I/HI powder. So
more acid solution needs to be added to dissolve the collagen (at pH 6-7, the collagen
powder forms big clusters).
Slurry 2% w/v collagen (200 ml total):
1) Add 2 ml 0.1 M HCl (0.1 M HCl --> 200pl of 6 M HCL into 11.8 ml of distilled
water) to 188 ml of distilled water at 4'C.
2) Add 4-g of collagen powder to the above solution and stir in 200 ml beaker with
magnetic stir bar. Monitor pH while stirring.
3) Add 2 ml of 0.1 M HCl solution gradually to maintain pH of 3.
4) Blend slurry for 60 minutes at 14000 rpm. Refrigerate the system during the blending
with an ice bath.
5) Adjust the pH to 3 by adding 2-3 ml 0.1M HCl
6) Blend again for 60 minutes at 14000 rpm.
7) Centrifuge at 2000 rpm for 15 min to degas. Store the slurry at 4'C.
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Dehydrothermal Crosslinking Protocol
1. Place collagen material in aluminum foil packet. Leave packet open at top.
2. Place packet in vacuum oven (Isotemp Model 201, Fisher Scientific, Boston, MA).
3. Turn on vacuum. The vacuum oven should reach a final pressure of approximately 50
mTorr. Leave the matrix in the oven for 24 hours at 1050C.
4. At the end of the exposure period, turn off the vacuum and vent the chamber. Open the
vacuum door and immediately seal the aluminum foil bags. The matrix is now
crosslinked and considered sterile, so the matrix should only be handled under sterile
conditions from now on.
5. Store the matrix in a dessicator. Crosslinked matrices can remain indefinitely in a
dessicator prior to testing or use.
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JB-4 EMBEDDING AND SECTIONING FOR PORE ANALYSIS
REFERENCE: (Freyman, 2001; O'Brien, Harley, et al., 2004; O'Brien, Harley, et al.,
2005)
MATERIALS:
JB-4 A monomer solution (Cat. No. 0226A-800, Polysciences)
JB-4 A catalyst, (Benzoyl Peroxide, plasticized, Cat. No. 02618-12,
Polysciences)
JB-4 B embedding solution (Cat. No. 0226B-30, Polysciences)
SOLUTIONS:
- Infiltration solution,
- Equilibration solution:
- Embedding solution:
0.625 g of catalyst dissolved in 50 ml JB-4 solution A.
50:50 solution of infiltration solution and 100% ethanol
2 ml of JB-4 solution B dissolved in 50 ml catalyzed
solution A.
PROCEDURE:
1) Dehydration
Collagen matrix samples are dehydrated in 100% alcohol overnight at 4C.
2) Equilibration
Following dehydration, samples are equilibrated for 12 hours at 4'C in a solution 50%
ethanol/50% catalyzed JB-4 solution A.
3) Infiltration
Infiltrate in 100% catalyzed JB-4 solution A, 1-4 days at 4'C. Change solution every 12
hours.
To ensure a high degree of infiltration and especially with larger samples, this step should
be carried out on a rotator..
When infiltration is complete, tissue usually appears translucent and will sink to the
bottom of container.
4) Embedding
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Combine JB-4 catalyzed solution A: JB-4 solution B at a ratio of 25:1.
Mix well and pipet into plastic molds.
Place samples face down in plastic molds.
Ensure that sample orientation is maintained.
Solution begins to harden in approximately 30 minutes.
After the JB-4 mixture becomes viscous enough that the samples do not float, place
labeled metal or plastic block holders onto each well and place the plastic mold tray in a
refrigerator (4'C) and wait overnight.
Pop the blocks from the mold
Let the samples dry at room temperature for 1 day
5) Sectioning
Section very slowly with the microtome at 5um
Place the section in water bath + few drops ammonium hydroxyde
Set sections on glass slides
Let dry overnight before staining with aniline blue
6) Aniline Blue Staining
Materials:
e Aniline Blue (Fisher Cat. # A-967)
e Glacial acetic acid (Fisher Cat. # A A507-500)
e Cytoseal 60 (Electron Microscopy Sciences Cat. #18006)
Solutions:
e Aniline Blue
o 2.5 g aniline blue
o 2 ml glacial acetic acid
o 100 ml distilled water
o Filter before use.
" Acetic Acid 1% (v/v)
o 1 ml glacial acetic acid
* 99 ml distilled water
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Staining Procedure:
1. Dip in aniline blue solution for 3 min
2. Place in 1% acetic acid solution for 1 min
3. Dip 5-10X in 95% alcohol until most of background staining goes away
4. Dip 5-10X in 100% alcohol
5. Are dry while coverslipping
6. One dip in 100% ETOH before applying Cytoseal
7. Mount with Cytoseal 60 and coverslip. Try not to get air bubbles.
8. Dry in hood for 1 hour.
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Scaffold Pore Size Analysis by Linear Intercept Method
C.3.7 Capturing Images for Pore Analysis
EQUIPMENT
- Inverted optical microscope (Olympus, BX5 1)
- CCD color video camera
PROCEDURE
1. From each transverse and longitudinal section, capture 1-2 low magnification pictures
(x4) to get an idea of the entire pore distribution (suggested image size 1600x1200
pixels).
2.
C.3.8 Image Processing and Pore Analysis
SOFTWARE EQUIPMENT
- Adobe Photoshop 6.0
- Scion Image (Scion Corporation, www.scioncorp.com)
- Excel spreadsheet
- Linear intercept macro code
PHOTOSHOP STEPS
1. Open image file using Adobe Photoshop. The starting image file has a resolution of 150
pixels/inch, width and height 1600 and 1200 pixels respectively.
2. Sharpen image
a. From the Adobe Photoshop (AP) menu select Filter > Sharpen > Sharpen
3. Despeckle image
a. AP menu select Filter > Noise > Despeckle
4. Auto Contrast
a. AP menu select Image > Adjust > Auto Contrast
5. Threshold image
a. AP menu select Image > Adjust > Threshold. All pore struts should be clearly
visible at the end of this step.
6. Select and change color of pore walls
a. Change foreground color to red
b. Select the Paint Bucket Tool (Shift+G) in the tool palette. If the tool is not
visible, right click on the Gradient tool and then select the paint bucket.
c. Click on pore walls to change pore wall color to red. Select all walls.
7. Use the Magic Wand tool to select colored pore walls
a. Select the Magic Wand tool in the tool palette.
b. Left click on pore wall with magic wand to select
c. Right click on Image and select "Similar"
d. Right click on Image and select "Layer via Copy"
8. Change image size.
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a. AP menu select Image > Image size. Change size to 40%. For 1600x1200 this
will be 640x480 pixels. Do not change the resolution, i.e. make sure that the
resample image box is selected.
9. Create a new file.
a. AP menu select File > New. Fix the width and height to be the same as the
reduced size image, the resolution at 150 pixels/inch, and 8 bit color RGB and
contents white.
10. Use the Move Tool and drag "layer 1" to the new file.
11. Change to Grayscale
a. AP menu select Image > Mode > Grayscale > Flatten.
12. Change levels
a. AP menu select Image > Adjust > Auto Levels.
13. Save the new image as .Tiff file.
SCION IMAGE STEPS AND PORE ANALYSIS
1. Open Scion Image. Open .Tiff image.
2. Under Options menu, select "Threshold." Change threshold values until optimal image
of collagen struts is visible. Clean up any remaining spots using the erase tool, if
necessary. The pore analysis macro will not count any artifact under 5 pixels across, so it
is not necessary to remove every stray spot.
3. Under Process menu, select "Make Binary" under the "Binary" sub-menu. This will
transform the thresholded image into a permanent binary image.
4. Under Special menu, select "Load macros", and open the "pore characterization macros"
(see below for macro code).
5. Set the scale for the analysis using the "Set Scale" option under the Analyze menu. The
microscope scale is calibrated as follows:
Objective No. Pixels Known distance (mm)
magnification
4X 216 1
lox 540 1
20X 108 0.1
40X 218 0.1
6. Select an area of the image to be analyzed using the oval drawing tool. To get a circle,
hold down the shift key while using the oval tool. Try to get as much of the image in the
selected area as possible.
7. Under "Special" menu, run Linear Intercept. This will produce the pore radii along lines
at various angles emanating from the center of the selected region. Next, run Plot
Intercepts macro. This macro will plot the average pore radii as a best-fit ellipse and will
calculate the linear intercept coefficients Co, C1, and C2.
8. Transfer Co, C1, and C2 data to an Excel spreadsheet for each matrix sample. Calculate
the minor and major radii of the ellipse, a and b, as well as the aspect ratio AR, using the
following equations:
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1a CO + C2 2
VC +C 2
b OJ = 2 _C
CI C +C2 + C2 -C
AR =max(a,b)
min(a,b)
(Equation C.2)
(Equation C.3)
(Equation C.4)
9. Calculate the average pore size using the following equation. The correction factor 1.5 is
necessary to take into account pores that are not sectioned through their maximum
diameter. The factor 2 changes from pore radius to pore diameter:
d =1.5x2x a b
2
(Equation C.5)
10. Calculate the orientation index, 01, and the angle of orientation of the ellipse, 0, by using
the following equation:
OI= 2cos2 9-1=cos29=± _ 2IC| +C2 (Equation C.6)
Linear Intercept Macro Code
This macro plots the linear intercept distance as a function of the angle 0 in cylindrical
coordinates and then produces the best-fit ellipse through multiple linear regression of the
following equation:
2 = Co + C, cos239+ C2 sin 2,9L
(Equation C.7)
where L is half the linear intercept at angle 0. Eqs. (2) and (3) are derived by calculating the
maximum and minimum values of L.
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Cross-linking Collagen Scaffolds by Carbodiimide Treatment
Summary
"Contrary to the use of bifunctional reagents like GA (gluteraldehyde), [carboxylic acid
activation] methods do not result in the incorporation of cross-linking agents in the
material... Cross-linking using [EDAC] involves the activation of the carboxylic acid
groups of glutamic or aspartic acid residues... Cross-links are formed after nucleophilic
attack by free amine groups of lysine or hydroxylysine residues" (Olde Damink, et al.
1996).
References
Olde Damink, et al., Biomaterials, 1996; 17: 765-73.
Lee, et al. Biomaterials, 2001; 22: 3145-3154.
Materials
* 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC)
MW = 191.7 g/mol (Sigma #E-7750; stored in desiccator at -20"C)
* N-hydroxysuccinimide (NHS)
MW = 116g/mol (Sigma #H-7377; stored in dessicant at room temp)
* Sterile, distilled water
0 50 ml centrifuge tubes or smaller if only cross-linking few matrices
e Phosphate Buffered Saline (PBS; Invitrogen #4190-250)
0 Sterile filter (0.22D m) and sterile container
0 Sterile pipettes and pipetteman
Procedure
1. Let EDAC warm to room temperature for about 30 minutes before use in order to
prevent condensed moisture inside bottle.
2. Hydrate matrices using sterile, distilled water.
3. Calculate the amounts of EDAC and NHS required for desired molar ratios of
EDAC:NHS:COOH, according to the following equations:
#Scaffoldsx g collagen mol COOH mol EDAC g EDAC =#Saflsxx x x =-gEDAC
scaffold g collagen mol COOH mol EDAC
#Scaffoldsx g collagen mol COOH mol NHS g NHS#Safodsxx x x = g NHS
scaffold g collagen mol COOH mol NHS
Notes: We make the assumptions that the scaffolds are primarily collagen (i.e., the mass
of other components is negligible), and that there are 1.2mmol COOH per mole of
collagen (see Olde Damink). Typical values for mass of 8mm scaffolds is 2-3 mg.
Typical calculations for molar ratios of 5:2:1 would be as follows:
0.002g collagen 0.0012mol COOH 5 mol EDAC 191.7g EDAC50 scaffolds x = x 0.115g EDAC
scaffold g collagen 1 mol COOH mol EDAC
0.002gcollagen 0.0012molCOOH 2 mol NHS 116g NHS50 scaffolds x xxx= 0.278g NHS
scaffold g collagen 1 mol COOH mol NHSC
Notes: The amounts of EDAC and NHS required are frequently very small and difficult
to weigh out, especially when only a small number of scaffolds are required. It is often
easier to weigh out a larger amount of the chemicals, dissolve in dH20, and dilute to the
desired concentration.
4. Dissolve EDAC and NHS in dH20.
The final volumes should be lml solution per scaffold.
5. Sterile filter EDAC/NHS solutions into sterile containers.
6. Transfer hydrated matrices to EDAC/NHS solutions.
Hydrated scaffolds will retain a small volume of water within the pores, which will
cause the final concentration of the EDAC/NHS solution to be very slightly diluted. If
this is a concern, hydrate the scaffolds in half of the final volume (i.e. 0.5ml dH2O per
scaffold), prepare the EDAC/NHS solution at 2X the final desired concentration, and
add the solution directly to the water in which the scaffolds being hydrated.
7. Pipette solution over matrices to ensure good mixture.
8. Cross-link at room temperature for desired time. (3.5 hours)
9. After cross-linking, transfer matrices to 50ml centrifuge tubes. Rinse matrices in
sterile PBS. Pipette out PBS and put fresh PBS and allow removal of residual
NHS/EDAC solution by rocking on nutator for about 1 hr.
10. Remove PBS and rinse in sterile dH 20 for 10 minutes twice.
11. Store matrices in sterile dH20 at 4*C for up to one week (effects of longer storage
unknown, usually used within 1 days of cross-linking).
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Adult Neural Stem Cell Culture
MEDIA: The basal media used is DMEMI/F12 (Invitrogen, Cat. # 11320-082)
containing 1 mM 1-glutamine and antibiotics (1% penicillin-streptomycin (Sigma, Cat. #
P4333),). To this is added N2 supplement (1%) (Invitrogen, Cat. # 17502-048). Avoid
filtration of the DME/F12-N2 as the supplements in N2 adhere to the filters. Add FGF-2
as needed just before use.
SHIPPING: We ship frozen cells. Please to not thaw the cells until proper media and
coated plasticware is on hand.
THAWING: The cells are frozen and shipped in N2 media containing 10% DMSO.
The vial should be thawed quickly in a 37 C waterbath with gentle agitation. Transfer
the cells to a 15 ml sterile centrifuge tube and gradually (dropwise) add an equal volume
of DME/F12 to the cells and mix gently. Let sit to equilibrate osmolarity for about 3-5
minutes. Dropwise add DME/F12 to a volume of about 10 ml and centrifuge at 1OOOg
for 2 minutes to pellet the cells. Resuspend the pellet in 1 ml N2 media using a medium
to small bore, flame polished, sterile Pasteur pipette and gentle tituration. Transfer the
cell suspension to a coated T75 flask or P00 dish containing 8-10 ml of N2 media with
20 ng/ml FGF-2. Incubate at 37 C in 5% C02.
CULTURING: The cells are routinely cultured in N2 media with 20 ng/ml FGF-2
(Note: same media used in thawing). Change the N2/FGF-2 media every 2-3 days.
Passage the cells when they reach about 90% confluency.
PASSAGING: Aspirate the media unless conditioned media is needed. Do not wash
the cells. A wash of the cell surface is made using 1-2 ml 0.05% trypsin-EDTA or
TripLE (Invitrogen) very gently spread over the cells and immediately taken off gently.
Incubate at room temperature for about 1-2 minutes then slap the flask against the palm
of the hand to dislodge the cells. Care is taken to dislodge and collect all the cells by
checking under the microscope. Suspend the cells in 5 ml DME/F12, transfer to a 15 ml
sterile centrifuge tube, wash the flask with 5 ml fresh DME/F12 and add to the cell
suspension. Centrifuge at 10OOg for 2 minutes. Resuspend the pellet in 1 ml N2 media
with gentle tituration using a medium to small bore, flame polished Pasteur pipette.
Transfer the cells to a new coated flask containing fresh media with 20 ng/ml FGF-2. We
passage cells at a dilution of about 1:5 depending on the confluency of the culture being
passaged.
FREEZING: Follow the passaging protocol above to get a suspension of the cells.
Instead of plating the cells, resuspend cells in N2 media containing 20 ng/ml FGF-2 and
10% dimethylsulfoxide (DMSO). Transfer to 1-1.8 ml freezing vials, put the vials in a
freezing chamber (Nunc) and put the freezing chamber in a -70 C freezer overnight. The
next day transfer the vials to a liquid nitrogen freezer.
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DIFFERENTIATION: Differentiate the cells to give three lineages by removing the
FGF-2 media from cells and replacing it with (or plating directly into) media to which
has been added 0.5% FBS and 1 uM retinoic acid (all trans). Feed with this media every
2-3 days. Differentiation is complete after about 6 days. For specific lineages use the
following reagents and concentrations for 4 days:
Neurons luM retinoic acid + 5uM forskolin or 1mM VPA
Astrocytes 50 ng/ml Lif + 50 ng/ml BMP2 + 0.5% FBS
Oligos 500 ng/ml IGF1
COATING: All plastic or glassware used to grow the cells must be coated with poly-L-
ornithine (sigma, #P36655) and mouse Laminin (1mg, Fisher #354232) as follows:
DAY 1
1) Dissolve for P-Om in H20 to make a stock solution (10 mg/ml). This
stock can be stored at -20 C.
2) Dilute PORN from stock concentration (10mg/ml) to yield:
a) 10 ug/ml for polystyrene or other plastics
b) 50 ug/ml for glass
3) Add enough Porn solution to the cultureware to cover the whole
surface.
4) Leave overnight (12-24 hours).
DAY 2
1) Wash the cultureware 2X with sterile H20.
2) Dilute the Laminin in sterile PBS to yield 5 ug/ml
(same concentration for both plastic and glass)
3) Add enough Laminin/PBS solution to the cultureware to cover the
surface.
4) Leave overnight (24 hours).
DAY 3
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1) Store the cultureware in the Laminin/PBS solution at -20 C by wrapping
plates and dishes in stretch wrap or tightening the caps on the flasks.
2) Cultureware coated and frozen at -20 C are good for up to 6-8 months.
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Wetting type I/III scaffolds prior to cell seeding
1. Place scaffolds in 50 ml tube filled with 100% Reagent alcohol. Leave overnight
on rotator (slow) at 4'C. (air bubble are removed from scaffolds and the scaffolds
sink to the bottom)
2. Remove alcohol and rinse 2x with sterile distilled water.
3. Fill 50 ml tube (containing scaffolds) with sterile distilled water and leave
overnight on rotator at 40C.
4. Remove water and add 50 ml sterile PBS. Leave overnight on rotator at 40C.
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Seeding Cylindrical Scaffold with Adult Neural Stem Cells
1. Pre-wet scaffold (see protocol)
2. Place scaffolds on sterile filter paper to dry. Scaffolds will shrink as the PBS is
absorbed by filter paper. Move scaffold to agarose coated (see protocol) cell
culture dish and lay flat.
3. Pipette cell suspension to the ends of the scaffold very slowly using a 20 1
pipette tip. For 5-6 mm scaffold with 3 mm diameter use 16 pl on each side.
Scaffold will regain its original size and shape at it absorbs the cell suspension.
4. Allow scaffolds to sit for 15 minutes prior to adding culture medium.
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Incorporating GDNF Plasmid into Collagen Scaffolds for Spinal Cord Implantation
1) Hydrate GenePORTER 2 lipid vial at room temperature with 1.5 ml Hydration Buffer
2) Vortex hydrated GenePORTER 2 reagent on high speed for 10 seconds (store at 4C)
3) Dilute 45 g1 hydrated GenePORTER 2 reagent with 60 p1 DMEM-lg. Mix well by
pipetting.
4) Dilute 5 pl DNA (plasmid for GDNF at concentration of 2.5 gg/pl) with 60 pl DNA
Diluent B. Mix well by pipetting.
5) Just prior to implantation into rat spinal cord defect take one 3-mm diameter, 5-mm long
scaffold and dry on sterile filter paper.
6) Mix 13 p1 of diluted DNA and 21 pl of diluted GenePORTER 2 reagent
7) Let sit at room temperature for 5 minutes (no longer than 30 min)
8) Add mixed solution to 1 dried scaffold with micro-pipette (will contain 2.5 Rg plasmid
GDNF DNA/scaffold)
9) Implant into rat spinal cord defect.
138
Tissue Decalcification (15% EDTA, pH 7.4)
To 3000ml PBS (Sigma P3813) (make up PBS from powder)
Add 600gm EDTA (Fisher S311-10) and 96gm NaOH (Fisher S318-5)
Stir till in solution, alternately adding EDTA + NaOH in small amounts (until completely
dissolved).
pH to 7.4 with HCL (-40-60mls)
Bring volume to 4000mls with PBS
Store at 4C
Change decal solution every other day for 10 to 14 days
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Poly/Bed812 Embedding Protocol
SOLUTIONS
Cacodylate Buffer (pH 7.4)
Stock Solutions:
Stock A (0.2 M Sodium Cacodylate - mw 214): 4.28 grams Sodium Cacodylate
(powder)
100 ml of Distilled Water
Stock B (0.2 M HCl - mw 36.46): 1.7 ml HCl
100 ml of Distilled Water
Composition of Buffer:
50 ml of Stock A + 1.4 ml of Stock B (for pH 7.4)* + 48.6 ml Distilled Water
* = Volume of Stock B changes for different pH levels
Final Molar Composition of Working Cacodylate Buffer Solution, pH 7.4:
O.1M Sodium Cacodylate
-0.0028M HCl
Cacodylate Buffered Glutaraldehyde
2% Solution: 8 ml 25% Glutaraldehyde
92 ml working cacodylate Buffer
Osmium Tetroxide Solution (Catalog No. 251755, Sigma-Aldrich, St. Louis,MO)
1% Solution: 2 ml 4% Osmium Tetroxide
6 ml working cacodylate buffer
Note: Can use 1-2% Osmium Tetroxide in 0. IM buffer
Poly/Bed 812 Embedding Kit (Catalog No. 08792, Polysciences, Inc., Warrington, PA)
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Catalog # Standard Formula
Poly/Bed 812 08791 24 ml
DDSA 00563 15.5 ml
NMA 00886 10.5 ml
DMP-30* 00553 1.0 ml
Procedure
1. Soak nerves in 2% cacodylate buffered glutaraldehyde 2-4 hours at 4C (or on ice).
2. Rinse nerves 3 times in 0.1 M working cacodylate buffered solution, 5 min each.
3. Fix in 1-2% osmium tetroxide solution for 1-2 hours at room temperature (in the hood)
in dark.
4. Rinse nerves 3 times in 0.1 M working cacodylate buffered solution, 5 min each.
*Can hold here (at 4'C) for a few days if necessary*
5. Dehydrate nerves in Reagent Alcohol:
70% 5 minutes
80% 10 minutes
90% 10 minutes
90% 10 minutes
100% 10 minutes
100% 10 minutes
100% 10 minutes
6. Clear nerves in acetone 2 times, 5 minutes for first exposure, 10 minutes for second.
BEWARE: Use fresh acetone for procedure. Acetone tends to pick up
water overtime, resulting in the formation of micro-pockets of water along
surface of nerve, impeding Epon infiltration.
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7. Infiltrate in 1:1 acetone/Epon mixture at room temperature for 5-24 hrs (rotate).
8. Infiltrate in 100% Epon for 8 hours at room temperature (rotate). Note: the 100% epon
solution will get increasingly viscous with time, therefore do not infiltrate for too long.
9. Embed in TEM molds (with fresh 100% Epon).
10. Let cure 24 hours at 60'C in oven (standard pressure).
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Hematoxylin and Eosin (H & E) Staining
Formalin fixed, paraffin embedded specimens
Solutions
Hematoxylin: Gill's Hematoxylin Solution, Sigma Cat# GHS216-500ml. Filter 200ml
of stock solution into staining dish.
Eosin: Eosin Y Solution Aqueous, Sigma Cat# HT1 10232-1L
Acid Alcohol: 0.5 % in 80% alcohol (99.5ml of 80% alcohol + 0.5 ml HCl)
Other Materials
Cytoseal: Cytoseal 60, Cat# 18006, Electron Microscopy Sciences.
Methods
1. Deparaffinize and Rehydrate
Xylene (or substitute)
100% alcohol
95% alcohol
80% alcohol
Wash in tap water
2. Hematoxylin, 3 min. Note:
3. Wash in tap water for 5 min.
4. Decolorization: 3 dips in acid alc
5. Wash in tap water for 5 min.
6. Eosin, 45 seconds.
7. Dehydrate
100% alcohol
Xylene (or substitute)
8. Coverslip with Cytoseal
2 x 5 min.
2 x 3 min.
2 x 2min.
1 min.
5 min.
be sure to filter hematoxylin prior to use!
:ohol.
2 x 3 min.
2 x 3 min.
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Masson's Trichrome Method for Staining Collagen Fibers
Description: This method is used for the detection of collagen fibers in tissues such as
skin, heart, etc. on formalin-fixed, paraffin-embedded sections, and may be used for
frozen sections as well. The collagen fibers will be stained blue and the nuclei will be
stained black and the background is stained red.
Fixation: 10% formalin.
Section: paraffin sections at 4-6 pim.
Solutions and Reagents:
(Note: most of the following solutions can be purchased premade from Sigma)
Weigert's Iron Hematoxylin Solution:
Stock Solution A:
Hematoxylin ------------------ 1 g
95% Alcohol ------------------ 100 ml
Stock Solution B:
29% Ferric chloride in water --------- 4 ml
Distilled water ------------------ 95 ml
Hydrochloric acid, concentrated ---- 1ml / 25% v/v
Weigert's Iron Hematoxylin Working Solution:
Mix equal parts of stock solution A and B. This working solution is stable for 3
months
Biebrich Scarlet-Acid Fuchsin Solution:
Biebrich scarlet, 1% aqueous ------ 90 ml
Acid fuchsin, 1% aqueous --------- 10 ml
Acetic acid, glacial --------------- 1 ml
Phosphomolybdic-Phosphotungstic Acid Solution:
5% Phosphomolybdic acid -------- 25 ml
5% Phosphotungstic acid --------------- 25 ml
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Aniline Blue Solution:
Aniline blue -------------------- 2.5 g
Acetic acide, glacial --------------- 2 ml
Distilled water ------------------ 100 ml
1% Acetic Acid Solution:
Acetic acid, glacial -------------- ml
Distilled water ------------------ 99 ml
Method:
1. Deparaffinize and rehydrate as usual:
a. Xylenes (2 x 5 minutes)
b. 100% Ethanol (2 x 3 minutes)
c. 95% Ethanol (2 x 2 minutes)
d. 80% Ethanol (2 x 1 minutes)
2. Wash in cold running tap water for 5 minutes.
3. Stain in Weigert's Hematoxylin working solution for 10 minutes.
4. Rinse in warm running tap water for 10 minutes.
5. Stain in Biebrich scarlet-acid fuchsin for 5 minutes. (Solution can be
reused)
6. Wash in cold running tap water for 5 minutes.
7. Differentiate in phosphomolybdic-phosphotungstinic acid for 20 minutes.
8. Transfer slides directly (without rinse) to aniline blue for 20 minutes.
9. Differentiate in 1% acetic acid for 2 quick dips
10. Dehydrate:
a. 2 dips in 95% Ethanol (2X)
b. 100% Ethanol (2 x 1 minute)
c. Xylenes (2 x 1 minute)
11. Mount with resinous mounting medium.
Results:
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Collagen -> Blue
Nuclei -> Black
Muscle, Cytoplasm -> Red
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Rat Bone Marrow Mesenchymal Stem Cell Harvesting and Culture
Materials:
- Head cap
- Sterile gloves
- Sterile towels
- Beta-dyne spray
- Sterile scrub
- Rat board
- Binding rubber bands
- Sterile gauze
- Size 15 scalpel blades
- 70 micrometer cell strainer
- 50 ml centrifuge tube
- Ice cold PBS
- 20 gauge needle
- 5 ml syringe
Growth medium (warm):
- 400 ml low-glucose DMEM
- 100 ml FBS
- 5 ml antibiotics - Penicillin/Streptomycin/anti-fungus
- Add last minute: 10 ng/ml FGF2
Rat Bone Marrow MSCs Harvest and Culture:
1. Sacrifice young rat (< 7 weeks old) with CO 2
2. Shave rat lower back and entire leg area
3. Place rat on surgery board in prone position and bind with rubber bands
4. Sterilize skin with beta-dyne solution
5. Using a size 15 blade, cut through the skin of the legs from the dorsum of foot to
above the hip
6. Remove both tibias and femurs
7. Place tibias and femurs in sterile ice-cold PBS in 50ml centrifuge tube and take to
sterile hood
8. Thoroughly clean attached muscle, periosteum, cartilage, and ligaments
9. Make a small hole with a 20 gauge needle at each end of the tibias and femurs
10. Using a 20 gauge needle attached to a 5ml syringe, insert needle into one end of
bone and flush with 5ml medium (for each tibia and femur) into a 50ml tube
11. Triturate BM in solution with pipette
12. Filter solution with 70 micrometer filter.
13. Spin the solution at 1500 rpm for 10 min
14. Discard supernatant
15. Resuspend the cells in 1 ml PBS (using a 1000 pl pipette tip to gently break down
pellet) then add 14ml of PBS to rinse the cells
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16. Centrifuge again at 1500 rpm for 10 min
17. Discard supernatant
18. Resuspend the cells in 1 ml growth medium (using 1000 pl pipette tip to gently
break down pellet) then add an additional 14ml growth medium
19. Seed the cells from one rat onto a 75cm2 flask in 15ml growth medium
20. Incubate at 37'C and 5% Co 2.
21. Remove non-adherent cells after 24 hours by medium aspiration and gently rinse
3x with 15ml warm PBS followed by adding 15ml fresh culture medium
22. Change culture medium every other day
23. Passage cells once they reach approximately 70-80% confluence
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Immunohistochemical Autostaining of a-SMA
Solutions
Tris-Buffred Saline(TBS) Stored at RT in
packets
(1 package Dakocytomation, S3001) to IL dH20 Stored at 4 "C in soln.
Used for diluting the Protease XIV and rinsing slides
Before putting them on the autostainer
IX Wash Buffer Stored at 4 "C
(Dakocytomation, S3006, 1000ml)
400ml of 1OX Wash Buffer in 3600ml dH20
Used for washing the slides in the autostainer. If you do not use wash buffer with tween
your
slides will not get washed properly and will show a very high background stain. The 1OX
Wash Buffer does not say it has tween in it but you should see bubbles.
0.1% (w/v) Protease XIV Stored at -
200C
10 mg Protease (Sigma, P5147)
10 ml TBS
Used for epitope retrieval. It helps enhance the staining of your antibody.
Peroxidase Blocking Reagent Stored at 4 'C
(Dakocytomation, Envision Plus+ System-HRP (AEC) K4005)
Used for blocking endogenous peroxidase in tissues.
0.03% hydrogen peroxide containing sodium azide.
Ready to use.
Protein Block Serum-Free
(Dakocytomation, Protein Block Serum-Free X0909) Stored
at 4 OC
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Used instead goat or horse serum.
Protein Block Serum-Free uses casein, a hydrophilic protein shown to decrease
nonspecific binding of primary antibody and secondary reagents.
Ready to use.
Primary Antibody (Mouse Monoclonal anti- a-SMA) Stored at -
200C
(4.5 g/L, Sigma A2547) - Lot #: 097k4860
use 1:200, 1:400 dilutions [equivalent to 22.5 tg/ml and 11.25 g/ml respectively]
(Note: 1:400 seemed to work fine - see staining pictures for comparison)
Antibody Diluent Stored at 4 "C
(Dakocytomation, S0809)
Used to dilute all antibodies! Has a little BSA in it.
Negative Control Mouse IgG2a Stored at 4'C
(100 mg/L, Dako, X0943)
Dilute in antibody diluent to same concentration as primary antibody:
Use 11.25 ptg/ml -- 112.5 pl in 887.5 ml diluent
LSAB2 System-HRP: Biotin Link and Streptavidin-HRP Stored
at 40C
(Dako, LSAB2 System-HRP K0609)
For use on rat specimens with primary antibodies from rabbit and mouse (biotinylated
anti-rabbit and anti-mouse immunoglobins)
Ready to use.
AEC Plus Substrate Chromagen
Dakocytomation, Envision Plus+ System-HRP (AEC) K4009) Stored at 40C
3-amino-9-ethylcarbazole containing hydrogen peroxide.
lOx more sensitive than AEC Chromagen
Ready to use.
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Counter stain
Mayer's Hematoxylin (Filter before use) Stored at RT
(Sigma: MHS 16-500ML)
Tap Water
Pretreatment of the slides
Deparaffinize and rehydrate via the following:
L IXylene(or substitute) 2x5 min
L L 100% EtOH 2x3 min
I [95% EtOH 2x2 min
LI L80% EtOH 1 min
L L wash in tap water 5 min
Note: From this point on, do not let slides dry out
Setting up the autostainer
1. Switch on computer
2. On the Desktop click on "DAKO Autostainer"
3. Login: Dong; password: Dong
4. Select "Program" on Main Menu
5. Click on "File", in the pull down menu click on "Open" and choose "rhc-sma2"
6. The template will show you 12 slides: slide 1 for the negative control and slides 2-5 for
positive staining.
7. To add slides click on "Slides" and type in the number of slides you want to stain
including all controls.
8. Copy and past the staining protocol by first clicking on "copy" than on the slide you
want
to copy. Clicking on any slide will automatically "paste" the protocol to any desired
row.
9. Click on "Next"
10. "Rinse Missing" window will appear, Click on "Yes"
It is important to make sure that there is no rinse after the Serum Block in order to
reduce
unspecific background stain.
The Program will no show the "Program Slides" Screen
Standard setting will use 15 0 pl per treated section of each slide. The standard setup of
the
machine will treat the 3/3 of the slide (marked yellow). If you want to change this:
11. click on the slide while holding "ctrl"
Or clicking on the slide in the top left corner. This will change all slides the same way.
12. Click on "Next"
The Program will show you how much Washing Buffer is needed to run the program.
Check bottle in cupboard under Autostainer. If necessary make some new Wash Buffer,
then click on "OK"
The "Load Reagents" Screen will show amount and the location in rack #1 of any reagent
used in the protocol. The Autostainer will calculate the amount of reagent required
according to the number of slides being stained.
13. Prepare solutions and click on "Next"
14. Load slides on coverplate as shown on "Load Slides" Screen. Make sure to keep
slides wet with TBS.
15. click on "Next" after loading slides
16. Click on Prime Pump (Buffer) and Prime Pump (Water) to home the machine!
17. Click on "Start Run"
Single steps performed by autostainer
0 0 DRinse (TBS+Tween)
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* E DAdd 0.1% Protease - 30 min.
* E [ Rinse (TBS+Tween)
e O OPretreatment Protein Block Serum-Free - 10 min.
0 1 lNO RINSE
* O1 OIAnti-aSMA (Primary antibody or negative mouse control) - 30 min.
0 l [ Rinse ((TBS+Tween)
e U OEnyme Block: H202 - 10 min.
* O 0 Rinse ((TBS+Tween)
0 O OBiotinylated Link anti-mouse - 15 min.
* l Rinse ((TBS+Tween)
e l l Streptavidin-HRP - 15 min.
* L E Rinse ((TBS+Tween)
* El Switch
0 EL LI Substrate: AEC Plus - 10 min (can go as long as 30 min.)
Counter staining and mounting
18. After running the program, immediately remove slides and put into TBS to keep wet.
19. Rinse in running tap water for 5 min
20. Counter-stain with Mayers Hematoxylin for 1.5 min (remember to filter before use)
21. Rinse in running tap water for 3 min.
22. Transfer "Slideholder" into a container with tap water and immediately
23. Coverslip with Aqueous Mounting Media (Faramount, Dako S3025)
Don't use Cytoseal for mounting as this will take your AEC Staining off!
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Immunohistochemical Autostaining of CD68
Solutions
Tris-Buffred Saline(TBS)
packets
(1 package Dakocytomation, S3001) to IL dH20
Used for diluting the Protease XIV and rinsing slides
Before putting them on the autostainer
Stored at RT in
Stored at 4 'C in soln.
1X Wash Buffer Stored at 4 "(
(Dakocytomation, S3006, 1000ml)
400ml of 1oX Wash Buffer in 3600ml dH20
Used for washing the slides in the autostainer. If you do not use wash buffer with tween
your
slides will not get washed properly and will show a very high background stain. The 10
Wash Buffer does not say it has tween in it but you should see bubbles.
0.1% (w/v) Protease XIV
200C
10 mg Protease (Sigma, P5174)
10 ml TBS
Used for epitope retrieval. It helps enhance the staining
Dako Dual Endogenous Enzyme Block
Catalog#: S2003
Used for blocking endogenous peroxidase in tissues.
Ready to use.
Stored at -
of your antibody.
Stored at 4 "C
Protein Block Serum-Free
(Dakocytomation, Protein Block Serum-Free X0909)
at 4 "C
Used instead goat or horse serum.
Protein Block Serum-Free uses casein, a hydrophilic protein shown to decrease
nonspecific binding of primary antibody and secondary reagents.
Ready to use.
Primary Antibody (Mouse IgG1 anti-CD68 monoclonal antibody)
Stored at -80 "C
(0.5 [g/1, AbD Serotec, Cat: MCA341R)
Use dilution of 1:200 [1:200 equals a concentration of 2.5pg/ml]
Stored
Stored at 4 "CAntibody Diluent
(Dakocytomation, S0809)
Used to dilute all antibodies! Has a little BSA in it.
154
X
Negative Control Mouse IgGi Stored at 4'C
(100mg/L, Dako, X0931)
Dilute in antibody diluent to same concentration as primary antibody: 25 [d IgG1 in 1 ml
diluent = 2.5 ptg/ml
Labelled Polymer-HRP anti-mouse Stored at 4'C
(Dakocytomation, Envision Plus+ System-HRP (AEC) K4005)
Used in place of the Biotin Link and SA HRP.
Peroxidase labeled polymer conjugated to goat anti-mouse immunogloblulins in Tris-Hcl
buffer containing stabilizing.
Ready to use.
AEC Plus Substrate Chromagen
Dakocytomation, Envision Plus+ System-HRP (AEC) K4009)
3-amino-9-ethylcarbazole containing hydrogen peroxide.
lOx more sensitive than AEC Chromagen
Ready to use.
Counter stain
Mayer's Hematoxylin (Filter before use)
(Sigma: MHS 16-500ML)
Tap Water
Stored at 4'C
Stored at RT
Pretreatment of the slides
Deparaffinize and rehydrate via the following:
0 D Xylene(or substitute) 2x5 min
D D 100% EtOH 2x3 min
0 0 95% EtOH 2x2 min
D D080% EtOH 1 min
SL0 wash in tap water 5 min
Note: From this point on, do not let slides dry out
Setting up the autostainer
1. Switch on computer
2. On the Desktop click on "DAKO Autostainer"
3. Login: Dong; password: Dong
4. Select "Program" on Main Menu
5. Click on "File", in the pull down menu click on "Open" and choose "rhc-cd68"
6. The template will show you 26 slides: 1 for the negative control and #2-26 for the
positive staining
7. To add slides click on "Slides" and type in the number of slides you want to stain
including all controls.
8. Copy and past the staining protocol by first clicking on "copy" than on the slide you
want
to copy. Clicking on any slide will automatically "paste" the protocol to any desired
row.
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9. Click on "Next"
10. "Rinse Missing" window will appear, Click on "Yes"
It is important to make sure that there is no rinse after the Serum Block in order to
reduce
unspecific background stain.
11. The Program will now show the "Program Slides" Screen. Standard setting will use
15 0pl per treated section of each slide. The standard setup of the machine will treat the
3/3
of the slide (marked yellow). If you want to change this: click on the slide while
holding
"ctrl" or clicking on the slide in the top left corner. This will change all slides the same
way.
12. Click on "Next"
The Program will show you how much Washing Buffer is needed to run the program.
Check bottle in cupboard under Autostainer. If necessary make some new Wash Buffer,
then click on "OK"
The "Load Reagents" Screen will show amount and the location in rack #1 of any reagent
used in the protocol. The Autostainer will calculate the amount of reagent required
according to the number of slides being stained.
13. Prepare solutions and click on "Next"
14. Load slides on coverplate as shown on "Load Slides" Screen. Make sure to keep
slides wet with TBS.
15. click on "Next" after loading slides
16. Click on Prime Pump (Buffer) and Prime Pump (Water) to home the machine!
17. Click on "Start Run"
Single steps performed by autostainer
El 0 Rinse (TBS+Tween)
1 OAdd 0.1% Protease - 20 min.
0 0 Rinse (TBS+Tween)
El OPretreatment Protein Block Serum-Free - 10 min.
O ONO RINSE
E ElAnti-CD68 (Primary antibody or negative mouse control) - 30 min.
El ORinse ((TBS+Tween)
El 0 Dual enyme block - 10 min.
E 0 Rinse ((TBS+Tween)
E E Rinse ((TBS+Tween)
E E Labelled Polymer-HRP anti-mouse - 30 min.
0 O Rinse ((TBS+Tween)
E El Switch
0 E Substrate: AEC Plus - 10 min (can go as long as 30 min.)
Counter staining and mounting
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18. After running the program, immediately remove slides and put into TBS (or tap
water) to keep wet.
19. Rinse in running tap water for 5 min
20. Counter-stain with Mayers Hematoxylin for 1.5 min (remember to filter before use)
21. Rinse in running tap water for 3 min.
22. Transfer "Slideholder" into a container with tap water and immediately
23. Coverslip with Aqueous Mounting Media (Faramount, Dako S3025)
Don't use Cytoseal for mounting as this will take your AEC Staining off!
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Immunofluorescence Autostaining of GAP-43
Solutions
Citrate antigen retrieval buffer (Dako, Cat.# S1699) Stored at 4 "C
pH 6, loX concentrated
Dilute 1 part S 1699 to 9 parts distilled water
Adjust pH to 6.10 if needed (ok if between 6.0 and 6.20)
Tris-Buffred Saline(TBS) Stored at RT in
packets
(1 package Dakocytomation, S3001) to 1L dH20 Stored at 4 "C in soln.
Used for diluting the Protease XIV and rinsing slides
Before putting them on the autostainer
1X Wash Buffer Stored at 4 "C
(Dakocytomation, S3006, 1000ml)
400ml of lOX Wash Buffer in 3600ml dH20
Used for washing the slides in the autostainer. If you do not use wash buffer with tween
your
slides will not get washed properly and will show a very high background stain. The 1OX
Wash Buffer does not say it has tween in it but you should see bubbles.
Protein Block: 10% Donkey Serum in TBS
Primary Antibody (Sheep IgG anti-GAP-43 Polyclonal antibody)
Stored at -80 "C
(From Benowitz lab)
Used dilutions of 1:250
Diluent in 5% Donkey Serum + 0.1% Tween-20 in TBS.
Negative Control: Omit primary antibody
Secondary Antibody (DyLight 549-conjugated donkey anti-sheep IgG)
(1.5 mg/ml, Jackson ImmunoResearch, Cat#: 713-505-147)
Used dilution of 1:100
Diluent in 5% Donkey Serum + 0.1% Tween-20 in TBS.
DAPI Counterstain Solution
DAPI Stock Solution (5mg/ml or 14.3 mM) Stored at -20'C
DAPI Working Solution (100ng/ml or 300 nM in TBS): 1 d stock solution in 50ml TBS
Can store working solution (protected from light) for short periods at 4 "C.
Pretreatment of the slides
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Deparaffinize and rehydrate via the following:
0 [ Xylene(or substitute) 2x5 min
[ I0 100% EtOH 2x3 min
0 0 95% EtOH 2x2 min
0I 080% EtOH 1 min
l l wash in tap water 5 min
Note: From this point on, do not let slides dry out
Perform antigen retrieval
" Add 500 ml distilled water to pressure cooker basin
e Put 250 ml of Citrate Buffer solution into staining container
* Place slides in slide rack inside buffer solution and place container in pressure cooker
e Set pressure cooker to 121 C for 2 min.
" Once pressure cooker is done, remove slide container and let cool on counter for 10
mn.
* Remove retrieval solution and rinse 2X in room temperature TBS.
Outline tissue sections with PAP pen
Setting up the autostainer
1. Switch on computer
2. On the Desktop click on "DAKO Autostainer"
3. Login: Dong; password: Dong
4. Select "Program" on Main Menu
5. Click on "File", in the pull down menu click on "Open" and choose "rhc-GAP5"
6. The template will show you 48 slides: slide 1 for the negative control and #2-48 for
the
positive staining
7. To add slides click on "Slides" and type in the number of slides you want to stain
including all controls.
8. Copy and past the staining protocol by first clicking on "copy" than on the slide you
want
to copy. Clicking on any slide will automatically "paste" the protocol to any desired
row.
9. Click on "Next"
10. "Rinse Missing" window will appear, Click on "Yes"
It is important to make sure that there is no rinse after the Serum Block in order to
reduce
unspecific background stain.
11. The Program will now show the "Program Slides" Screen. Standard setting will use
150pl per treated section of each slide. The standard setup of the machine will treat the
3/3
of the slide (marked yellow). If you want to change this: click on the slide while
holding
"ctrl" or clicking on the slide in the top left corner. This will change all slides the same
way.
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12. Click on "Next"
The Program will show you how much Washing Buffer is needed to run the program.
Check bottle in cupboard under Autostainer. If necessary make some new Wash Buffer,
then click on "OK"
The "Load Reagents" Screen will show amount and the location in rack #1 of any reagent
used in the protocol. The Autostainer will calculate the amount of reagent required
according to the number of slides being stained.
13. Prepare solutions and click on "Next"
14. Load slides on coverplate as shown on "Load Slides" Screen. Make sure to keep
slides wet with TBS.
15. click on "Next" after loading slides
16. Click on Prime Pump (Buffer) and Prime Pump (Water) to home the machine!
17. Click on "Start Run"
Single steps performed by autostainer
Notes: 1) Keep chamber humidified by placing wet paper towels
2) Make section volumes 200 ul X 2
3)Keep lights off during run
i O Rinse (TBS+Tween)
L L Pretreatment Protein Block: 10% Donkey Serum in TBS - 120 min.
O ONO RINSE
O LiAnti-GAP-43 (Primary antibody or negative control) - 180 min.
L 0 Rinse ((TBS+Tween)
L l Rinse: 5% Donkey Serum + 0.1% Tween-20 in TBS - 90 min.
0 0 Rinse ((TBS+Tween)
O 0 Rinse: 5% Donkey Serum + 0.1% Tween-20 in TBS - 90 min.
0 0 Rinse ((TBS+Tween)
L []Rinse: 5% Donkey Serum + 0.1% Tween-20 in TBS - 90 min.
O 0 Rinse ((TBS+Tween)
Li ODyLight 549-conjugated anti-sheep (Secondary antibody) - 120 min.
Li ORinse ((TBS+Tween)
L O Rinse ((TBS+Tween)
O 0 Rinse ((TBS+Tween)
Li LDAPI - 30 min.
L O Rinse ((TBS+Tween)
L L Rinse ((TBS+Tween)
L L Rinse ((TBS+Tween)
l l TBS - 60 min.
SEl TBS - 60 min.
Mounting
18. After running the program, immediately remove slides and put into TBS to keep wet.
19. Coverslip with fluorescent mounting media
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Immunohistochemical Autostaining of GFAP
As an internal control use at least 1 slide of rat spinal cord as a positive and negative
control. This will assess the technical quality of the staining.
Solutions
Tris-Buffred Saline(TBS) Stored at RT in
packets
(1 package Dakocytomation, S3001) to IL dH20 Stored at 4 "C in soln.
Used for diluting the Protease XIV and rinsing slides
Before putting them on the autostainer
IX Wash Buffer Stored at 4 "C
(Dakocytomation, S3006, 1000ml)
400ml of 1OX Wash Buffer in 3600ml dH20
Used for washing the slides in the autostainer. If you do not use wash buffer with tween
your
slides will not get washed properly and will show a very high background stain. The 1OX
Wash Buffer does not say it has tween in it but you should see bubbles.
0.1% (w/v) Protease XIV Stored at -
20 0C
10 mg Protease (Sigma, P5174)
10 ml TBS
Used for epitope retrieval. It helps enhance the staining of your antibody.
Peroxidase Blocking Reagent Stored at 4 "C
(Dakocytomation, Envision Plus+ System-HRP (AEC) K4005)
Used for blocking endogenous peroxidase in tissues.
0.03% hydrogen peroxide containing sodium azide.
Ready to use.
Protein Block Serum-Free
(Dakocytomation, Protein Block Serum-Free X0909) Stored
at 4 "C
Used instead goat or horse serum.
Protein Block Serum-Free uses casein, a hydrophilic protein shown to decrease
nonspecific binding of primary antibody and secondary reagents.
Ready to use.
Primary Antibody (Polyclonal Rabbit Anti-Glial Fibrillary Acidic Protein)
Stored at 4 "C
(2.9g/L, Dako, Cat: Z0334)
Use a 1:1000 dilution [which equals a concentration of 2.9 mg/L]
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Stored at 4 "CAntibody Diluent
(Dakocytomation, S0809)
Used to dilute all antibodies! Has a little BSA in it.
Negative Control Rabbit Imunoglobulin (Ig) Fraction (Normal)
(20g/L, Dako, X0903)
Dilute in antibody diluent to same concentration as primary antibody
1 [d in Iml diluent [20g/L * lul = 20ig] -> next take 145 [d of this and
diluent to get 2.9 tg/mL
Stored at 4'C
add to 855 pl
Labelled Polymer-HRP anti-Rabbit Stored
at 40C
(Dakocytomation, Envision Plus+ System-HRP (AEC) K4009)
Used in place of the Biotin Link and SA HRP.
Peroxidase labeled polymer conjugated to goat anti-rabbit immunogloblulins in Tris-Hcl
buffer containing stabilizing.
Ready to use.
AEC Plus Substrate Chromagen
Dakocytomation, Envision Plus+ System-HRP (AEC) K4009)
3-amino-9-ethylcarbazole containing hydrogen peroxide.
lOx more sensitive than AEC Chromagen
Ready to use.
Counter stain
Mayer's Hematoxylin (Filter before use)
(Sigma: MHS 16-500ML)
Tap Water
Pretreatment of the slides
Deparaffinize and rehydrate via the following:
D OXylene(or substitute) 2x5 min
0 0 100% EtOH 2x3 min
[10 95% EtOH 2x2 min
D E 80% EtOH 1 min
D D wash in tap water 5 min
Note: From this point on, do not let slides dry out
Stored at 4'C
Stored at RT
Setting up the autostainer
1. Switch on computer
2. On the Desktop click on "DAKO Autostainer"
3. Login: Dong; password: Dong
4. Select "Program" on Main Menu
5. Click on "File", in the pull down menu click on "Open" and choose "rhc-gfap"
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6. The template will show you 29 slides; #1 for negative control and slides 2-29 for the
positive GFAP staining.
7. To add slides click on "Slides" and type in the number of slides you want to stain
including all controls.
8. Copy and past the staining protocol by first clicking on "copy" than on the slide you
want
to copy. Clicking on any slide will automatically "paste" the protocol to any desired
row.
9. Click on "Next"
10. "Rinse Missing" window will appear, Click on "Yes"
It is important to make sure that there is no rinse after the Serum Block in order to
reduce
unspecific background stain.
11. The Program will now show the "Program Slides" Screen. Standard setting will use
150l per treated section of each slide. The standard setup of the machine will treat the
3/3
of the slide (marked yellow). If you want to change this: click on the slide while
holding
"ctrl" or clicking on the slide in the top left corner. This will change all slides the same
way.
12. Click on "Next"
The Program will show you how much Washing Buffer is needed to run the program.
Check bottle in cupboard under Autostainer. If necessary make some new Wash Buffer,
then click on "OK"
The "Load Reagents" Screen will show amount and the location in rack #1 of any reagent
used in the protocol. The Autostainer will calculate the amount of reagent required
according to the number of slides being stained.
13. Prepare solutions and click on "Next"
14. Load slides on coverplate as shown on "Load Slides" Screen. Make sure to keep
slides wet with TBS.
15. click on "Next" after loading slides
16. Click on Prime Pump (Buffer) and Prime Pump (Water) to home the machine!
17. Click on "Start Run"
Single steps performed by autostainer
0 D Rinse (TBS+Tween)
OAdd 0.1% Protease - 30 min.
E 0 Rinse (TBS+Tween)
l OPretreatment Protein Block Serum-Free - 10 min.
O ONO RINSE
L OAnti-GFAP (Primary antibody or negative rabbit control) - 30 min.
0 O Rinse ((TBS+Tween)
L L Enyme block H20 2- 10 min.
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D ODRinse ((TBS+Tween)
D 0 Rinse ((TBS+Tween)
D 0lLabelled Polymer-HRP anti-rabbit - 30 min.
El ORinse ((TBS+Tween)
E El Rinse ((TBS+Tween)
D O Switch
L OI Substrate: AEC Plus - 10 min (can go as long as 30 min.)
Counter staining and mounting
18. After running the program, immediately remove slides and put into TBS to keep wet.
19. Rinse in running tap water for 5 min
20. Counter-stain with Mayers Hematoxylin for 2 min (remember to filter before use)
21. Rinse in running tap water for 3 min.
22. Transfer "Slideholder" into a container with tap water and immediately
23. Coverslip with Aqueous Mounting Media (Faramount, Dako S3025)
Don't use Cytoseal for mounting as this will take your AEC Staining off!
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Immunohistochemical Autostaining of Neurofilament
Solutions
Tris-Buffred Saline(TBS)
packets
(1 package Dakocytomation, S3001) to IL dH20
Used for diluting the Protease XIV and rinsing slides
Before putting them on the autostainer
Stored at RT in
Stored at 4 "C in soln.
1X Wash Buffer Stored at 4 'C
(Dakocytomation, S3006, 1000ml)
400ml of lOX Wash Buffer in 3600ml dH20
Used for washing the slides in the autostainer. If you do not use wash buffer with tween
your
slides will not get washed properly and will show a very high background stain. The 1OX
Wash Buffer does not say it has tween in it but you should see bubbles.
Protein Block Serum-Free
(Dakocytomation, Protein Block Serum-Free X0909)
at 4 "C
Used instead goat or horse serum.
Protein Block Serum-Free uses casein, a hydrophilic protein shown to decrease
nonspecific binding of primary antibody and secondary reagents.
Ready to use.
Stored
Primary Antibody (Mouse Monoclonal Anti- 200kDa + 160kDa
Stored at -80 "C
(1 g/L, Abcam, Cat: ab24570)
Use a 1:1000 dilution (=1Ig/ml) -+ 12l NF in 12 ml diluent
Antibody Diluent
(Dakocytomation, S0809)
Used to dilute all antibodies! Has a little BSA in it.
Neurofilament)
Stored at 4 "C
Negative Control Mouse IgGI Stored at 4'C
(100mg/L, Dako, X0931)
Dilute in antibody diluent to same concentration as primary antibody: 1 pg/ml -* 7pl
IgG1 in 693 l diluent
Labelled Polymer-HRP anti-mouse Stored at 4'C
(Dakocytomation, Envision Plus+ System-HRP (AEC) K4005)
Used in place of the Biotin Link and SA HRP.
Peroxidase labeled polymer conjugated to goat anti-mouse immunogloblulins in Tris-Hcl
buffer containing stabilizing.
Ready to use.
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AEC Plus Substrate Chromagen
Dakocytomation, Envision Plus+ System-HRP (AEC) K4009) Stored at 4'C
3-amino-9-ethylcarbazole containing hydrogen peroxide.
lOx more sensitive than AEC Chromagen
Ready to use.
Counter stain
Mayer's Hematoxylin (Filter before use) Stored at RT
(Sigma: MHS 16-500ML)
Tap Water
Pretreatment of the slides
Deparaffinize and rehydrate via the following:
D OXylene(or substitute) 2x5 min
D D 100% EtOH 2x3 min
0 0 95% EtOH 2x2 min
1 0I80% EtOH 1 min
L l wash in tap water 5 min
Note: From this point on, do not let slides dry out
Setting up the autostainer
1. Switch on computer
2. On the Desktop click on "DAKO Autostainer"
3. Login: Dong; password: Dong
4. Select "Program" on Main Menu
5. Click on "File", in the pull down menu click on "Open" and choose "rhc-nfl"
6. The template will show you 24 slides: slide 1 for the negative control and slides 2-24
for positive staining.
7. To add slides click on "Slides" and type in the number of slides you want to stain
including all controls.
8. Copy and past the staining protocol by first clicking on "copy" than on the slide you
want
to copy. Clicking on any slide will automatically "paste" the protocol to any desired
row.
9. Click on "Next"
10. "Rinse Missing" window will appear, Click on "Yes"
It is important to make sure that there is no rinse after the Serum Block in order to
reduce
unspecific background stain.
The Program will no show the "Program Slides" Screen
Standard setting will use 150gl per treated section of each slide. The standard setup of
the
machine will treat the 3/3 of the slide (marked yellow). If you want to change this:
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11. click on the slide while holding "ctrl"
Or clicking on the slide in the top left corner. This will change all slides the same way.
12. Click on "Next"
The Program will show you how much Washing Buffer is needed to run the program.
Check bottle in cupboard under Autostainer. If necessary make some new Wash Buffer,
then click on "OK"
The "Load Reagents" Screen will show amount and the location in rack #1 of any reagent
used in the protocol. The Autostainer will calculate the amount of reagent required
according to the number of slides being stained.
13. Prepare solutions and click on "Next"
14. Load slides on coverplate as shown on "Load Slides" Screen. Make sure to keep
slides wet with TBS.
15. click on "Next" after loading slides
16. Click on Prime Pump (Buffer) and Prime Pump (Water) to home the machine!
17. Click on "Start Run"
Single steps performed by autostainer
E [ Rinse (TBS+Tween)
O1 [ Pretreatment Protein Block Serum-Free - 10 min.
[I ONO RINSE
[I O Anti-NF (Primary antibody or negative mouse control) - 30 min.
LI l Rinse ((TBS+Tween)
O 0 Labelled Polymer-HRP anti-mouse - 15 min.
L [ Rinse ((TBS+Tween)
I L Switch
L LI Substrate: AEC Plus - 10 min (can go as long as 30 min.)
Counter staining and mounting
18. After running the program, immediately remove slides and put into TBS to keep wet.
19. Rinse in running tap water for 5 min
20. Counter-stain with Mayers Hematoxylin for 1.5 min (remember to filter before use)
21. Rinse in running tap water for 3 min.
22. Transfer "Slideholder" into a container with tap water and immediately
23. Coverslip with Aqueous Mounting Media (Faramount, Dako S3025)
Don't use Cytoseal for mounting as this will take your AEC Staining off!
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Immunohistochemical Autostaining of Von Willebrand Factor
Solutions
Tris-Buffred Saline(TBS)
packets
(1 package Dakocytomation, S3001) to IL dH20
Used for diluting the Protease XIV and rinsing slides
Before putting them on the autostainer
Stored at RT in
Stored at 4 "C in soln.
IX Wash Buffer Stored at 4 "
(Dakocytomation, S3006, 1000ml)
400ml of loX Wash Buffer in 3600ml dH20
Used for washing the slides in the autostainer. If you do not use wash buffer with tween
your
slides will not get washed properly and will show a very high background stain. The 10
Wash Buffer does not say it has tween in it but you should see bubbles.
0.1% (w/v) Protease XIV
200C
10 mg Protease (Sigma, P5147)
10 ml TBS
Used for epitope retrieval. It helps enhance the staining
Stored at -
of your antibody.
Peroxidase Blocking Reagent
(Dakocytomation, Envision Plus+ System-HRP (AEC) K4005)
Used for blocking endogenous peroxidase in tissues.
0.03% hydrogen peroxide containing sodium azide.
Ready to use.
Protein Block Serum-Free
(Dakocytomation, Protein Block Serum-Free X0909)
at 4 "C
Used instead goat or horse serum.
Protein Block Serum-Free uses casein, a hydrophilic protein shown
nonspecific binding of primary antibody and secondary reagents.
Ready to use.
Stored at 4 "C
Stored
to decrease
Primary Antibody (Polyclonal Rabbit Anti-Human Von Willebrand Factor)
Stored at 4 "C
(3.3 g/L, Dako, Cat: A0082)
Use a 1:100 dilution [Equals a concentration 33 mg/L]
Antibody Diluent
(Dakocytomation, S0809)
Used to dilute all antibodies! Has a little BSA in it.
Stored at 4 "C
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Negative Control Rabbit Imunoglobulin (Ig) Fraction (Solid-Phase Absorbed)
Stored at 4'C
(15 g/L, Dako, X0936)
Dilute in antibody diluent to same concentration as primary antibody: 33[tg/ml
2.2l = 33tg - 2.2pil in I ml diluent = 33pig/ml
Labelled Polymer-HRP anti-Rabbit Stored
at 40C
(Dakocytomation, Envision Plus+ System-HRP (AEC) K4009)
Used in place of the Biotin Link and SA HRP.
Peroxidase labeled polymer conjugated to goat anti-rabbit immunogloblulins in Tris-Hcl
buffer containing stabilizing.
Ready to use.
AEC Plus Substrate Chromagen
Dakocytomation, Envision Plus+ System-HRP (AEC) K4009)
3-amino-9-ethylcarbazole containing hydrogen peroxide.
lOx more sensitive than AEC Chromagen
Ready to use.
Counter stain
Mayer's Hematoxylin (Filter before use)
(Sigma: MHS 16-500ML)
Tap Water
Pretreatment of the slides
Deparaffinize and rehydrate via the following:
E DXylene(or substitute) 2x5 min
D D 100% EtOH 2x3 min
E [D95% EtOH 2x2 min
I 0180% EtOH 1 min
l l wash in tap water 5 min
Note: From this point on, do not let slides dry out
Stored at 4'C
Stored at RT
Setting up the autostainer
1. Switch on computer
2. On the Desktop click on "DAKO Autostainer"
3. Login: Dong; password: Dong
4. Select "Program" on Main Menu
5. Click on "File", in the pull down menu click on "Open" and choose "rhc-wvf'
6. The template will show you 48 slides; #1 for negative control and slides 2-48 for the
positive vWF staining.
7. To add slides click on "Slides" and type in the number of slides you want to stain
including all controls.
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8. Copy and past the staining protocol by first clicking on "copy" than on the slide you
want
to copy. Clicking on any slide will automatically "paste" the protocol to any desired
row.
9. Click on "Next"
10. "Rinse Missing" window will appear, Click on "Yes"
It is important to make sure that there is no rinse after the Serum Block in order to
reduce
unspecific background stain.
11. The Program will now show the "Program Slides" Screen. Standard setting will use
150pl per treated section of each slide. The standard setup of the machine will treat the
3/3
of the slide (marked yellow). If you want to change this: click on the slide while
holding
"ctrl" or clicking on the slide in the top left corner. This will change all slides the same
way.
12. Click on "Next"
The Program will show you how much Washing Buffer is needed to run the program.
Check bottle in cupboard under Autostainer. If necessary make some new Wash Buffer,
then click on "OK"
The "Load Reagents" Screen will show amount and the location in rack #1 of any reagent
used in the protocol. The Autostainer will calculate the amount of reagent required
according to the number of slides being stained.
13. Prepare solutions and click on "Next"
14. Load slides on coverplate as shown on "Load Slides" Screen. Make sure to keep
slides wet with TBS.
15. click on "Next" after loading slides
16. Click on Prime Pump (Buffer) and Prime Pump (Water) to home the machine!
17. Click on "Start Run"
Single steps performed by autostainer
E []Rinse (TBS+Tween)
LI L Add 0.1% Protease - 45 min.
O O Rinse (TBS+Tween)
O1 ] TBS - 60 min.
El El Rinse (TBS+Tween)
El O Pretreatment Protein Block Serum-Free - 10 min.
O1 ONO RINSE
D O Anti-vWF (Primary antibody or negative rabbit control) - 60 min.
El ORinse ((TBS+Tween)
El El Enyme block H20 2- 10 min.
E l [Rinse ((TBS+Tween)
L l Rinse ((TBS+Tween)
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D 0Labelled Polymer-HRP anti-rabbit - 30 min.
E 0 Rinse ((TBS+Tween)
0 0 Rinse ((TBS+Tween)
O O Switch
L LI Substrate: AEC Plus - 10 min (can go as long as 30 min.)
Counter staining and mounting
18. After running the program, immediately remove slides and put into TBS to keep wet.
19. Rinse in running tap water for 5 min
20. Counter-stain with Mayers Hematoxylin for 1.5 min (remember to filter before use)
21. Rinse in running tap water for 3 min.
22. Transfer "Slideholder" into a container with tap water and immediately
23. Coverslip with Aqueous Mounting Media (Faramount, Dako S3025)
Don't use Cytoseal for mounting as this will take your AEC Staining off.
